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The duration of drug action is generally limited by rate of conver-
sion of therapeutk agents to inactive metabolites, since most of the 
drugs must be metabolized before they are excreted in urine, breath, 
feces or.bile. Without biochemical systems for the metabolism of for-
eign compounds, much of our present drug therapy.would be dangerous and 
impracticable, since the action of most therapeutic agents would persist 
for an extended period of time. The metabolism of drugs in the body 
does not always result in detoxification, Some drugs, like codeine and 
ephedrine, are converted to metabolites having pharmacologic properties 
similar to those of the parent drug. Others, like imipramine and pron.,. 
tosil, produce their therapeutic effects only through.the formation of 
pharmacologically active metabolites, Some authors have used the term 
"toxification" to describe the process of the production of a more phar-
macologically active compound by metabolism of the administered drug, 
The elucidation of the pathways of.drug metabolism thus leads to a 
better understanding of drug action as well as to the mechanisms.of drug 
detoxification, 
Tranquilizers are the.drugs referred to as ataractic agents, Atar-
axia by.definition means "not disturbed", perfect peace or calmness of· 
mind (1), Fr.om the biochemical, point of view, tranquilizers can be 
divided into two main groups. There are two distinct biochemical 
1 
2 
mechanisms (2) .whereby t~ese compounds can.cause a.tranquilizing action:. 
The first group of compounds (e.g •. reserpine) are capable of liberating 
biologically active amines from brain cells, thereby exposing them to 
attack of metabol:i.zing enzymes, thus decreasing their.cerebral concen-
tration; a second group of tranquilizers (e.g. chlorpromazine) are bio-
chemically characterized by their ability to simultaneously inhil;>it both. 
oxidative phosphorylation and adenosine triphosphatase activity in.the 
brain. 
Chlorpromazine is an extremely important drug used in the treatment 
of mental illness. This tranquilizer has been used to treat some 50 
million people .. the world over; and has been shown. to be. metaboli~ed by 
several,mammalian species. The majo:i:- metabolites in higher animals in-
clude the sulfoxide, glucuronide derivatives of various hydroxy chlor-
promazines, the N-oxide and·demethylated metabolites. Urine samples of 
different species (3-:-6) showed the. following metabolites·. of CP: CP sul-
f~xide, nor1 and nor2-CP sulfoxides, nor1 and nor2-CP, glucuronides of 
7..;.hydroxy, nor1 and nor2-:-7-hydroxy chlorptomaz;l..nes and CP-.N-oxide. Gil-
lette and Kamm (7) observed the conversion of chlorpromazine to chlor-
promazine sulfoxide (CPSO) by guinea pig liver microsomes. Chlorproma-
zine-N-oxide formation by subcellular liver fractions was reported from 
this laboratory (8,9) and by Beckett and Hewick (10). 
This dissertat:i,.1;m will report the. results of studies on species 
diff.erences. in· chlorpromazine.-N-oxidation, demethylation and role of 
CPNO as an intermediate in o:ddatiye demethylation. This thesis will 
also report.· results on the isolation,· purification and determination of 
tbe kinetic properties of chlorpromazine-N-oxygenase from pig liver 
mocrosomes. Certain other characteristics such as the ·noninvolvement of 
3 
c:ytochrome.P-450, substrate specificity and pFl optimum will be reported. 
CHAPTER II 
irTERATURE REVIEW 
Metabolism of Drugs 
Drug metabolizing enzymes convert toxic and poorly excreted lipid-
soluble foreign compounds.to nontoxic, water soluble derivatives that 
can be eliminated more rapidly by the kidney. A large number of drugs 
and other compounds; foreign .to the body, are metabolized in mammals 
along a number of metabolic pathways which include sulfoxidation, N-oxi-
dation, dealkylation, deamination, hydroxylation, reduction, hydrolysis 
and conjugation forming glucuronides, sulfates, etc. Metabolism of· 
drugs has been reviewed.in detail by Brodie et&· (11) Gillette (12), 
and Shuster (13). Extensive review on phenothiazines was covered by 
Gordon (14), The literature review in this thesis will cover the dif-
ferent pathways of drug metabolism, comparative biochemistry of drugs, 
induction of drug metabolism and a short review of .tranquilizers. Phar-
macological and biochemical.effects and metabolic fate of chlorpromazine 
in~ and _!E:, vitro will also be reviewed. 
Studies with tissue preparations have revealed that most of the 
enzyme systems which catalyze these metabolic alterations.are present in 
liver microsomes, It is generally assumed.that the intact microsomal 
system requires only oxygen and NADPH or a generating system for maximum 
activity, However, Nilson and Johnson (15) claim that in addition to 
NADPE, NADH may also be required for maximal N-demethylation, 0-demethy-
4 
lation, and hydroxylation. A combination of NADH and NADPH was more 
effective than NADPH alone.in the N-demethylat;ion of 3-methyl-4-methyl-
amino benzene, (16). According to Waddell ~ al, (1'0, the activity of, 
microsomal N-demethylase can be .. increased considerably by incubation 
under oxygen instead of air, Of various rabbit tissues tried, namely 
liver, lung, kidney, heart, muscle and brain, only the microsomes.in 
liver catalyzed.the dealkylation of monomethyl-4-aminoantipyrene (18), 
5 
The microsomal fract+on of liver consists of subcellular components 
that are generally believed to be derived from the.endoplasmic reticulum, 
a,network of tubules which extends into almost all regions of the cyto-
plasm, The reticulum comprises two major components; A rough-surfaced 
form consisting of lipoid tµbules studded with small.dense particles 
called ribosomes; and a smooth.surfaced form.consisting of .lipoid tub-
ules devoid of ·ribosomes. On ·homogenization, the network of tubules is 
broken and forms small vesicles which can be isolated as 'rough' and 
'smooth' microsomes. Fout (19) separated the 'smooth' from the 'rough' 
microsomes and showed that.the drug enzyme systems are associated mainly 
with smooth microsomes, 
Oxidation 
Drugs undergo oxidation by a number,of metabolic pathways including 
sµlfoxidation, N-oxidation, deamination, dealkylation and hydroxylation. 
Th;f.o-ethers such·as chlorpromazine and 4,4'-diaminodiphenyl sulfide are 
oxidized to the corresponding sulfoxide derivatives (7). Baker and 
Chaykin (20) found that trimethylamine is oxidized to trimethylamine 
oxide, In N~dealkylation, alkyl groups are removed from secondary or 
tertiary amines-to formaldehydes and primary amines, Rat liver micro-
6 
somes contain an enzyme which is relatively.specific for tertiary amines. 
This enzyme.demethylates imipramine to.cl.esmethylimipramine (21). This 
enzyme presumably demethylates other compounds including chlorpromazine 
(22) and. amit:riptyline (23). In 0-dealkylation, alkyl groups of .. ethers 
are removed to formaldehydes and phenols. For example, p-ethoxy ace-
tanilide is oxidized to p-hydroxyacetanilide and acetaldehyde (24). 
Axelrod (25) observed that a number of amines are oxidized to ketones 
and ammonia by an.enzyme system which differs from monoamine oxidase not 
only in its requirement for NADPH, but also in its ability to deaminate 
a number of different substrates which are not metabolized by monoamine 
oxidase. This microsomal system is found in the rabbit liver, but not 
in hepatic tissues of the dog or rat. Mi tom.a ~ al. (26) showed hydrox-
ylation of acetanilide occu];'red both in the ortho and para positions. 
Besides aromatic compounds, hydroxylation of alkanes has also been 
reported. Gillette (27) found that the rabbit liver microsomal system 
ox:i,dized p-nitrotoluene to p-nitro benzyl alcohol. Toki et al. (28), 
reported that liver microsomes convert hexobarbital to 3-hydroxy hexo-
barbital, whic,h is then oxidized.to 3-keto hexobarbital by the soluble 
fraction. 
Rep.uction 
Liver microsomes also contain enzyme systems that catalyze the 
reduction of azo and nitro compounds. Nitro compounds such as chloram-
phenicol, p-nitrobenzoic acid and nitrobenzene are reduced to primary 
amines by an enzyme system which can use either NADH or NADPH as its 
hydrogen donor (29). Nitroso and hydroxylamine derivatives are presum-
ably·intermediates in this reaction, since the microsomal enzyme system 
reduced both nitrosobenzene and phenylhydroxylamine to aniline more 
rapidly than it does nitrobenzene (12). Azo-reductase and nitro-reduc-
tase are both flavoproteins having FAD aia their prosthetic group (30). 
However, azo-reductase requires NADPH as its hydrogen donor, while ni-
tro-reductase uses either NADPH or NADH (31).. In addition to microsmal 
oxidation, certain foreign compounds (e.g. chloral hydrate) are also 




A number of enzymes catalyze the hydrolysis of substrates (esters 
or.amides) by the addition of water. Hollunger and Niklasson (32) have 
succeeded in solubilizing and purifying several est~rases from rabbit 
liver microsomes, and they reported that these esterases d:iffered 
markedly in their substrate specificity. Bray~ al. (33) reported the 
presence of amidases in rabbit liver homogenates which hydrolyze a num-
ber of amides. The rate of hydrolysis of amides is usually slower than 
the cleavage of esters. For example, procaine amide (34) and salicyla~ 
mide (35,36) are very slowly deaminated in the body, 
Conjugation 
The formation of hippuric acid in the body by conjugation of gly-
cine and benzoic acid has been known for 100 years or more. Conjugation 
reactions include the formation of glucuronides, etheral sulfates, mer-
capturic acids, amino acid conjugates, acetylated amines and methylated 
compounds (12), The sythesis of glucuronides generally represents an 
important pathway.of metabolism for phenols, carboxylic acida, long chain 
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alcohols, primary amines, hydroxylamines and certain.thio compounds. 
Glucuronide formation occurs.mainly in liver (37), but it also takes. 
places in the kidney, gastrointestinal tract (38,39) and skin (40), 
Another important pathway in.drug.metabolism is sulfate·conjugationo In 
this reaction phenols.and alcohols are conve~ted to sulfate esters (41-
43) and aromatic amines to sulfamates (44-46). The synthesis of the 
sulfate derivatives occurs in the soluble fraction of liver homogenates· 
thx-ough the formation of adenosine-5'-phosphosulfate and.3'-phosphoade-
. nosine-5'-phosphosulfate~ Other pathways which play a minor role in 
drug metabolism are discussed by Gillette (12). 
Comparative Metabolism of Foreign Compounds 
Four species of fish and certain.types of amphibia, including frogs 
. and salamanders, failed to metabolize monomethyl-4-aminoantipyrine, 
aminopyrine, N-methylaniline, antipyrine, hexobarbital or p-ethoxyace-
tanilide (47). These compounds are presumably excreted unchanged 
thr,eugh.the gills or skin. Reptiles, including alligators.and tortoises, 
metabolize the above.drugs. The microsomes.of these animals contain an 
enzyme system for demethylating monomethyl-4~aminoantipyrine that re-
quires NADPH and oxygen. A dealkylating enzyme system with the.same 
requirements is also present ill the liver microsomes of birds (chicken, 
pigeon), the opossum and a large variety of other mammals (rabbit, rat, 
g1,1inea pig, and mouse) (47 ,.48). Quinn et al. (49) have shown that var-,-
ious strains of·rats metabolize antipyrine at markedly different rates. 
Age·and sex differences were also reported (12). New-born mice, ·rab-
bits and guinea pigs lack the liver microsomal enzyme systems for the. 
metabolism of.many.foreign compounds, including aminopyrine, phenacetin. 
and hexobarbital .. (50 ,51). The enzyme systems appear within the first. 
week after birth and increase until the maximum.is reached at eight. 
weeks. The·action of many drugs persists longer.in female.rats than.in 
male ·rats~ For ·example, Holck.!£;.!.!.· (52) showed that females, injectzed' 
with certain oxybarbiturates, sleep considerab1y longer than males.· In 
accord with this. findi11g, the ·liver microsomes of male rats metabolized · 
hexobarbital and aminopyrine considerably faster than did those of fe-
ma.les (49). The in vitro metabolism of·drugs by liver microsomes.can be 
inhibited by prolonging agents (e.g. SKF·525-A) and by a number of 
other mecnanisms discussed by. Gillette · (12). 
Stimulation of Drug Metabolism 
Treatment of animals with a·wide variety of foreign compounds ac-
celerates the biotransformation of drugs in vivo.by increasing the 
activity of the enzyme.systems that catalyze drug metabolism. St\ldies 
by Conney (53..-55) revealed that barbital and phenobarbital adminietered. 
orally to.rats increases the.activity of microsomal.drug enzymes which 
hydroxylate phenylbutazone and.3,4 - benzpyrene, as well as those which 
metabo.l;ize ami~opyrine and.hexobarbital, 
:{3rodie et al. (11) stated that a drug metabolite is almost invari-
ably more.polar (chloral hydrate.is an.exception since it.is reduced to 
more lipid soluble trichloroethanol in vivo) and, therefore, les1;1 toxic 
than the parent.compound.because it's decreased.lipid solubility pre-
vents it from passing cellular barriers and reaching a potential site 
of action. However, despite its increased polarity; the derived pro-
duct may have a pharma.cologic action which the parent·compound lacks if 
the conversion should, unmask or. produce.a new functional group. Thus, 
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prontosil is inactive but is converted to sulfanilamide which is active 
due to the unmasking of the p-amino group (56). Though most foreign 
compounds undergo metabolic conversion, certain drugs are excreted vir~ 
tually unchanged. These are usually strongly ionized compounds.like· 
priscoline and hexamethonium, and are chemically unreactive, They are 
rapidly excreted because their lipid insolubility precludes·extensive 
reabsorption by renal tubules. Other biochemically unreactive drugs 
like ethyl ether or cyclopropane are lipid soluble but are excreted un-
changed by the lungs (57), 
Solubilization of Drug Metabolizing Enzymes 
Conventional methods of solubilization inactivate many of the drug 
metabolizing enzymes in liver microsomes. A small number of enzymes 
that have been shown to retain their activity after solubilization have. 
been summarized by Shuster (13), In several instances the addition of 
cofactors to the. soluble enzymes is required for maximal activityo Imai 
and Sato (58) found.that the activity of lyophilized soluble aniline 
hydroxylase was destroyed by extraction with methanol-ether. Activity 
could be restored by addition of an extract of microsomal lipids. Solu~ 
ble acetanilidehydroxylase aho seems to require some.heat stablej dia-
lizable cofactor for maximal activity (59). Alkylarylamine oxygenase 
from pork liver microsomes was solt.1bilized using sonication procedure 
followed by addition of ·Triton X-100 by Ziegler et al. (60). This en~ 
zyme fraction was further purified by aI!lmonium sulfate fractionation, 
The enzyme preparation thus purified about 1000 fold, was ·free from de-:-
alkylating enzyme, monoamine oxidase and NADPH-cytochrome C reductase •. 
With .this preparation, they· demonstrated the oxidation ·.of wide variety 
11 
of drugs on the basis NADPH oxidation (61). 
Tranquilizing Drugs 
Two agents are responsible for introducing a revolution in psycho-
therapy. These are reserpine, an alkaloid of Ra'l,lwolfia serpentina, and 
chlorpromazine, a synthetic drug related to the antihistamines. The 
introduction of Rauwolfia alkaloids (isolated from the whole root) in 
western medicine began in 1953 and chlorpromazine was introduced in the 
following year. However, the use.of roots and extracts from the Indian 
Rauwolfia serpentina Benth, a climbing shrub, as tranqu,ilizers goes back 
for many centuries (62), Th:i,s activity was first mentioned in western 
literature by Rumpf·. (63). Mueller and associates (64) reported the iso-
;J.ation of a new alkaloid res.erpine, from Rauwolfia seq~entina. Reser-
pine is essentially antihypertensive as well as being a tranquilizing 
drug. 
Phenothiazine Derivatives 
The development of the alkylated phenothiazines as psychopharmaco-
logical agents occurred about the same time as the introduction of re-
serpine. The former development stemmed from the observation that cer~ 
tain antihistaminic compounds had sedative side effects. In attempts to 
enhance the sedative effects .of these phenothiazines, notably prometha-
zine, chlorpromazine was synthesized. An indication of the qualitative 
differences between promethazine and the psychopharmacological phenothia-
zines like chlorpromazine is seen in the fact that promethazine is char-
acterized by pronounced antihistaminic activity and a relative lack of 
blockage of a conditioned escape response. In contrast chlorpromazine 
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is a weak antihistaminic but shows pronounced antiemetic and conditioned 
response blocking activity. It is thus remarkable that s~ll differences 
in chemical structure produce marked qualitative.changes in pharmacolog-
:I.cal effects.(65-68), · Pharmacology and metabolism of phenothiazines as 
a group S.D:9- chlorpromazine in.particular were discussed in detail by 
Gordon (14), More than 3000 diffei::ent phenothiazines have been synthe-
sized to date and.a detailed review of these has been published by 
Schenker and Herbst (6g). 
Promethazine Chlorpromazine 
Pharmacological Effects of Chlo:rpromazine 
The first pharmacological investigations of chlorpromazine were 
conducted by Courvoisier and colleagues (70). The most important effect 
of chlorpromazine is its singular sedative effect (71). Animals become 
quiet and sleepy, remain in unnatural positions (so-called catalepsy) 
and at higher doses fall asleep. In the brain, chlorproma.zine is said 
to act through the hypothalamus,and the limbic system. One·of the most 
important effects i$ on the central nervous.system. Chlorpromazine 
causes a reduction in motor activity. In mice 1";"5 '\llg/kg of chlorproma-:-
13 
zine, adm;Lnister~d orally or subcut,neously, produced a reduction in 
spontaneous lUOtor. activity proportional to the dose (72). Decerebrate . . 
and diencephalic cats were ni.ore sensitive to .the depressant effects.of. 
chlorpromazine than normal animals (73), Chlorpro'Qlazine antagonizes the 
emetic effec:i:s.of certain drugs, irradiation and motion sickness in 
animals, The antiemetic ef f.ect, of chlorp:romazine is due primarily to .. 
depression or inhibition of .the medullary.chemoreceptor.trigger.zone, 
However, there appears to.be some'inhibitory activity on-the vomiting 
,·,,:!,, :1 •• 
center at elevated. dosages. A 50 mg dose of . .CP gave ·almost complete pro-. 
tection to a group of human subjects against the .emetic effects of one 
mg of apomorph;l..ne administered subcutaneously (74). Effects.· of ·chlor-
promazine on the ·activity of .other drugs was discussed by Gordon (14). 
Chlorpromazine lowers body temperature in various laboratory animals 
(75). Chlorpromazine has been found by Elder·and Dille (7:6) .and by 
Schwartz et al. (77) to antagonize the be.havioral effects of .LSD, al-
. --
though CP inhibits the me~abolism of-LSD (78), Pharmacological effects. 
' . 
of ·chlorprolllazine on autonomic nervous, cardiovascular, ·endocrine, gas-
trointestinal, hepatic and neuromuscular systems ,were discussed by 
Gordon (14) .. Van Woert reported that long term chlorpromazine adminis .... · 
tration in man.is iiSSociated with oculocutaneous P,igmentation and the 
accumulation of brown pigment deposits in variQU$ :organs. These pigment 
granules were isolated from the liver of a sch;J.zQphrenic: patient treated.· 
wi.th chlorp,:,omazine. The ultrav.iolet absorption waxima were 304 and 254 
mµ. for one pigment and 261 nµ for the o.ther. Two of the chlorpr.omazine 
pig'!llent polymers pre.pared in· vitr<> l;>y the . aerobic irradiation of . an aqu- · 
eous solutic.m of CP HCl by ultraviqlet light for 18 hours showed similar 
ultraviolet and infrared absorption •?ectra (79). · 
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The .approximate 14-day tn50 of CP in rats by various.routes are 
intraperitoneal, 75-100 mg/kg; subcutaneous, 540 mg/kg; oral, 492 mg/kg; 
and intravenous, 25. mg/kg (80), Hollister. (81) has stated that ''sue::cese-
ful suicide with phenothiazine derivatives is virtually unknown despite 
doses of 10-20 gm; among central nervous system depressants, these drugs 
. are as .. suicide-proof as any might be," 
Biochemical Effects of Chlorpromazine 
Chemistx:y. 
Chlorpromazine (2-chloro-10~(3-dimethylaminopropyl)phenothiazine) 
was .synthesized .by Charpentier of the Rhone..:.Poulenc Laboratories in. 
France in 1950 (82). CP, like phenothiazine and most of ·its derivatives, 
is light sensitive. One,method of synthesis for chlorpromazine may be 
represented as follotvs (83) :. 
i,~ 
~SYcY . ·_..,...· 12"""'"--. Sb.--) ~' . • (cy 
~N~Cl ~~~Cl· 
H ij 
+ .4 - isomer, 
Chlorpromazine 
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Chlorpromazine hydrochloride in solution exhibits maximum chemical 
stability when buffered at a pH of·. 4 to 5 and protected by the presence 
of antioxidants, It is sensitive to all oxidizing agents including fer-
ric salts, persulfuric acit:l, permanganates, dichromates, ;nitric acid and 
hydrogen peroxide. Characteristic colors are formed and may be.used as· 
a spot test for identification purpose$, The·free base begins to pre-
cipitate.as the pH of a solution approaches q. CP has an absorption 
maximum at 257.5 mµ. in the ultraviolet region (83). 
Effects of Chlorpromazine on Membrane Permeability 
It has been su~gested that chlorpromazine alters the permeability 
of various membranes to substances lfl<;e norepinepl:l.rine and serotonin, 
and the antipsychotic activity of chlorpromazine has been attributed to 
its membrane effect~ (84). Evidence was presented demonstrating a sta-. 
bilization of.the r,t liver lysosmal.n,embrane by CP both .!E_ vivo and in• 
vitro (85). L{&vtrup observed that DNP and Mg++ activated ATPase, succin-
ate dehydrogenase and aspartate transaminase were inhibited by CP, Sue-
cinate dehydrogenasi; was·less sensitive when the mitochondria were dis-
rupted by treatment with digitonin, whereas sensitivity of the Al'Pase· 
activity was significantly increased, S"Uccin~te dehydrogenase and cer-
tain other enzymes were activated considerably by low concentrations of. 
CP. This activation, inhibition phenomenon is possibly due to interfer~ 
. ! 
ence with the.structure of the mitochondrial membrane~ ;Further, he also 
observed a substantial change.in the permeability coefficient of cell 
. . 
membranes in n2o permeability experiments at lov, concentrations of CP 
(Sp). 
Enzyme Effects. 
Enzyme studies on brain tissue of animals depressed.with chlorpro-
-
ma;ine revealed that creatine phosphokinase activity and the ,activities 
of enzymes catalyzing the.dephosphorylation of adenine nucleotides. were 
unaltered by the drug and it. was concluded. that·· chlorpromazine in. some. 
way depresses .the utilization of ·brain ATP, so that a.given stimulus 
results ·in· less uti~ization of labile phosphate (87.). Lazzalo anc;l Meyer .. 
(88) reported th~t CP · both ,.inhibits and potentiates ·the act.ivity of. D-
amino acid oxidase. Kurokowa et!!· (89) have found that another flavin 
enzyme, succinic dehyroge-q.ase, was ... also both inhibited and ,potentiated by 
CP. Further, Harris (90) reported that inbibition of CP·(final concen-
tration of 4 x 10-:-4M) on 0-amino acid oxidase in.competition with ite 
coenzyme, FAD, was a function of.the apooxidase protein concentration. 
Inhibit.ion was also decreased when albumin was added to the reaction mix ... 
ture. Therefore, it was suggested that this nonspecific complexing be-
tween CP and protein might.explain the large number of diverse effects 
attributed to CP •. Chlorpromazine was found to inhibit the activity of,a 
liver enzyme. that N-methylates. nicotinamide .• (91). The· surface tensions 
of solutions of .. CP have been shown te> decrease in the presence of ATP 
due to reversible formation of a complex~ The reaction with ATP,was 
specific and probably was a result of salt formation between the phos-
phate. groups. of ATP and. the quat.ernary nitrogen of the dimethylam:f,no 
propyl side chain·of.CP (92). CP decreases the,activity of ·acetylcho-. 
line este:rase (93) and acid phosphatase·(94). Greenberg ,il.-al~ (95) re-. 
ported that CP had little effect on glutamic acid decarboxylase, but did 
inhibit: pyridoxal kinase.activity in.both normal.and B6-deficient rat 
brain homogenates. Chlorpromazine;· li~e 2,4 - dinitrophenol, has been 
shown.to produce uncoupling of oxidative phosphrylation in various pre-
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parations of brain and liver and also inhibits ATPase activity (96,97). 
CP inhibitecl. partially purified cytochrome oxidase from rat liver,mito-
chonc;iria (98). 
Structure-Activity Relationshil)S 
Brl;lne ~!.!..· observed that.progressive demethylation of CP is as-
sociated with an increasing loss of pharmacological potency. Conversely, 
toxicity was found to. be highest for nor2 CP followed by nor1 CP and CP 
in decreasing order (99). Thus, it e.pp1;:ars that the N,N-dimethyl con-
figuration plays a major role in the.pharmacological effectiveness of 
CP. Replacement of the dimethyl amino propyl chain·of CP by the N-meth-
yl""'.piperazinopropyl chain of.prochlorperazine gave an increase in activ-
ity and a decrease in acute toxicity (100). Burke showed that substitu-
tion in 2""'.position of phenothiazine seems optimal.for activity. The 
substituents had about the following OJ:"der.'°f activity (101), 
CF 2 > Cl > H Fl:l OCH3 Fl:l CONHNI:fa 
Moran and Butler have·showen that the sulfoxide produces.only.slight· 
pharmacological effects in comparison with chlorpromazine (102). Phar-
macological and behavioral tests on nor1 CP and CPNO indicated that 
these compounds approach CP in act:ivity, whereas CPSO is markedly less 
Absorption, Distribution and Metabolism of Chlorpromazine 
Absorption a.nd: Distrib:u.tion 
a.. 
i', 
Chlorpromazine is rather slowly ab.sorbed from the gastrointestinal 
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tract and is retained at the site of subcutaneous i:njection for an ex-
tended period of time. :Peak blood· levels are reached in 20 minutes 
after intraperitoneal injection. From the ·blood, CP is readily trans-,. 
ferred to the tissues where the concentrations, especially in brain, far 
transcend.those in the blood. Dogs receiving 20 mg of CP/kg intraven-,-
ously gave tissue/plasma ratios with approximately the following values. 
at one hour after injection: brain, 66:1 to 68:1; lung, 45:1 to 55:1; 
kidney and spleen 15:1 to 33:1; liver, skeletal muscle, and heart, 7o5:l 
to 14: 1 and perirenal fat 2. 5: 1 to 5, 0: L The drug disappears relative-
ly slowly from the tissues. 'Henrickson ,!t al. reported that small·quan-
tities of residual CP hydrochloride were fouqd in the fat, brain, heart, 
lung and kiqney of those animals rec.eiving O. 4 mg/lb body weight when 
slaughtered 8 hours aft.er injection. Animals held for 72 hours had no 
detectable residual compound in any of the tissues (103). Man excretes. 
little or .no unchanged chlorpromazine in the urine, dogs .excrete not 
more than l.,5%, and rats about 15%, in 5 days (104). The cerebral level 
of Cl? is 13 µ. g/ g after the administration of 5 mg/kg of the drug and 85 
µ,g/g aft.er. a dose of 20 mg/kg. It's distribution within the brain is 
not uniform, the hypothal.amic areas containing 4 to 5 times as much of 
the drug as other parts of· the brain· (2). · Intramuscularly and. intraven-,-
35 ously administered S-chlorpromazine in mice accumulated initially in 
the cerebral cortex, hippocampus and.thalamic:.nuclei of the brain as 
well as in'the adrenal cortex, liver, lung and ki4ney. Radioactive met~ 
abolites later.appeared in the lymph nodes, spleen and thymus (105)0 
35s · · f 35 s· hl i ' bl' d -activity rom · -c orpromaz ne or its Il}eta q ic pro. ucts was rap-
idly and widely distributec;l in the tissues of the mouse. Spleen and 
brain retained the highest levels of activity up to 5 days after the 
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administration of 35s-chlorpromazine (196). 
After injection of rats and guinea pigs with chlorpromazine (5-10 
mg/100 gms body weight), Wechsler il al. (107) determined CP and its 
metabolites .in various organs •. The liver.and lungs contained in addi-
tion to unchanged CP, nor1 CP, CPSO an~ nor1 ,cPSO. In the kidney nor1 
CP was missing and only CP was.found in brain. Ill addition, in guinea 
pig liver exclusively, a relatively polar hyqro~ylated CP compound with 
the same Rf as 7-hydroxy CP and 8-hydroxy CP'was consistently observed. 
Ninety minutes after i.p.injection, it was found tq.at nor1 CP accumu"7 
lates in the brain to.a greater extent than CP, nor2 CP or CPSO. The 
enhanced accumulation of nor1 GP in brain cannot be COIJ!pletely accounted 
for in terms of a blood-brain barrier phenome1J.on ·(l08). 
Metabolic Fate of Chlorpromazine 
Salzman and Brodie showed chlorpromazine sulfoxide to.be a metabo-
lite of chlorpromazine in the dog and man. (109). H,ydrolysis of dog and 
human urine by acid, alkali or ~-glucuronidase treatment increases the 
amount of prienothiazine-like extractable compounds (110). These conju-
gated·compounds represent a large fraction of the chlorpromazine meta-
bolites excret.ed in the urine, Further, compounds were isolated from 
the urine of patients on chlorpromazine therapy and were characterized 
as glucuronic,acid conjugated chlorpromazine tp.eta~olites (111), Fish-
man and.Goldenberg (112) have studied an organic,eitractable fraction 
; ·; ! :, 
from the urine of patients administered chlorpro111a21i,ne, Following or""'.' 
ganic extraction of·alkalinized human urine, chromatographic studies 
revealed the presence of ten compounds which produce a .. Dragendorff color 
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reaction, Six of these appear to be sulfoxides, including CPSO which 
was.a minor product, Two major metabolites had chromatographic behavior 
indistinguishable from nor1 . C:PSO and nor2 CPSO •. · A third major metabo-
lite remains unidentified. It was found.that the residual urine after 
extraction contained numerous additional.polar metabolies. 
35 The·metabolic fate.of S-chlorpromazine was studied in the rat 
(4). Four excretion products were determined qualitatively by chromato-
graphy and quantitatively as. a percent of the dose: CP(l2. 3%); CPSO 
(5%); nor1 CPS0(5,2%); and nor2 CPS0(2.3%). The Baso4 precipitates from 
the urines contained only insignificant amounts of radioactivity~ Gold-
enberg and Fishman (3,113) identified the following metabolites of. chlor-
promazineby comparison with reference compounds: 7-hydroxy CP, 7-hydro-
xy·cpso, nori 7-hydroxy.CP and nor2 7-hydroxy CP. These compounds were 
excreted both in the.free form and as glucuronic aGid conjugates. Huang 
et al. (114) have speculated, on the basis of potent:i,.al oxidizability, 
that hydroxylation in~ takes place a1: the 3 - or 7 - positions. 
They have found, in man that glucuronides are major metabolites, Dogs 
excrete two series of phenolic derivatives of chlorpromazine. One.is 
hydroxylated at position 7(major site), the other at position 3. The· 
human·phenolic metabolites are.principally of the.7-hydro~y series (115), 
Fishman et al. (6) and Posner et al. (5) reported the isolation and 
identification of chlorpromaz;l.ne-N-oxide from human.urine. This com-
pound, although .. not a major human. metabolite, is excreted in somewhat 
larger amounts. than CPSO, Dogs surpass humans in .. tpeir output of the N-
oxide. The metabolism of chlorpromazine was.compared in dogs and man.by 
Goldenberg and Fishman· (116). Humans tend to favor excretion of polar 
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·derivatives,. together with one or two major nonpolar. 1ll.etabolites.,nor1 and 
nor2 CPSO, The human.output of chlorpormazine and its sulfoxide was. 
trivial. Dogs excreted less polar material, less nor2 CPSO, more nor1 
CPSO, and substantial amounts of both chlorpromazine and its sulfoxide. 
Human.polar fractions contained persulfate-blue as,well as persulfate-
laverider staining metabolites; the blue series was absent from dog urine. 
Three new metabolites of chlorpromazine have.been isolated from the 
urine of mental.patients by Johnson~ al. (117), These were identified 
as 2-chlorophenothiazine, 2-chlorophenothiazine sulfoxide and 2-chloro-
phenothiazine-10-propionic acid, The first two metabolites; of interest 
because th~ complete loss of the side chain, were isolated by extracting 
alkaline urine 'With dichloromethane; and the acidic compound was ex-,-
tracted from urine at pH 3 with chloroform. Extraction of.urine at 
acidic pH's removed at least three other acidic phenothiazines in addi-
tion .to the propionic acid metabolite. The identity of these are as 
yet unconfirmed, Fishman and Goldenberg (115) also reported that chlor.:... 
promazine undergoes side-chain cleavage.as a minor route of metabolismo 
In addition to 2-chlorophenothiazine sulfoxide and 2-chlorophenothiazine, 
they observed 2-chloro-7-hydroxy-phenothiazine, 2-chloro-phenothiazone 
and 2-chlorothionol, Thus, by different combinations of hydroxylation, 
demethylation, sulfoxidation, N-oxidation and side chain cleavage~ 
chlorpromazine is metabolized into more than 20 metabolites. Extensive 
work on the urinary analysis of CP metabolites has been done on human· 
and dog (3-6). In summary the concentration of major urinary metabo-




Pola~ metabolites: nor1 and nor2 7-0H CP> 7-0H CPSO > 7-0H CP 
Non polar· metabolites: nor 2 . CPSO > nor l CPSO > CPNO > CPSO > CP 
Polar metabolites: 7-0H CP series > 3-0H CP series 
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Non ·polar .metabolites:- nori CPSO • · CP$0 > CPNO = CP > nor2 CPSO 
Non· polar metabolites: CP> nor 1 CPSO > CPSO > nor 2 CPSO 
The -.metabolic fate of chlorpromazine in mammalian species is shown 
. in . Figure 1, . 
Analytical Methods for Identification and Determination 
of Chlorpromazine Metabolites. 
The detection and estimation of chlorpromazine metabo;Lites contin-
ues·toreceive much attention as new·metabolite1:1 are being discovered. 
No satisfactory comprehensive systelll8tic procedures have·yet-been devel-
oped. Paperf thin layer.and now gas chromatography have become increas-
ingly popular. Dubost and Pascal (llS,,119) have found that sulfuric 
acid develops a.red color with phenothiazines and have reported that 
this color is stabilized by the . addition of ethanol or formaldehyde •. 
Various other oxidative reagents were also used to detect phenothiazines 
(14). Detection of chlorpromazine in body fluids (120) and a spectro-
photometric method for chlorpromazine determination in biological mate-
rial has been reported (10~,121). Van Loon developed a.spectrophotomet-
ric me_thod for the determination of chlorpromazine and chlorpromazine 
sulfoxide in biological · fluids based on th~ ultraviolet : spectra of. 
these compounds (122). A new extraction method using dichloromethane. 
Figute 1. Metabolic Fate.of Chlorpromazine in 
Mammalian Species. 
CP .. Chlorpromazine; 
CPSO .Ill Chlc;,rproi:nazine sulfoxide; 
CPNO "". Chlorpromaziri.e-N-Oxide ;, 
nor1 == . Monodemethylated; 
nor2 == Didemethylated; 
-OH == HydX'oxy 
A ·== 7-0H, CP; 
B .. 7-0H, CPSO; 
c == 7-0li, nor CP; 1 
D == . 7-0H, nor1 CPSO; 
E == 7-0H, nor2 CP 
F .. 7-0H, nor2 .CPSO 
G =: 2-Chlorophenothiazine sulfoxide; 
H =. 2-Chloro-7-0H, phenothiazine; 
I .. 3-0H, CP; 
J = :. 2-Chlorophenothia~ine; 
K == Thionol; 
L = Phenothiazone; 
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and tetrahyq.rofuran wasrecently used for isolation of chlorpromazine 
metabolites from urine by Johnson~ al. (123). A method for the deter, 
mination of urinary chlorpromazine and its metabolites employing absorp-
tion on Dowex 50 W-X4 cation exchange resin was,described by Forrest et 
al. (124). Chlorpromazine and chlorpromazine sulfoxide were sepaiated 
by paper chromatography, The chromatograms were,dried and sprayed with 
50% H2so4 . Approximately one,inch squares including the spots,of CP and 
CPSO were cut out, extracted with 3.5 ml of 50% H2so4 and filtered, 
Thus, the compounds were determined quantitatively, by measuring the 
acid extracts.at ·525 mµ in."Spectropic 20" (125). Eisdorfer and Ellen-
bogen (126) described a paper chromatographic procedure for separation 
of CP, nor1 and nor2 CP; CJ?SO, nor1 and nor2 CPSO, CP sulfone; nor1 and 
nor2 CP sulfone. Posner ~ .!!.· separated nonphenolic and phenolic meta-
bolites of chlorpromazine from human urine by paper chromatography, The 
chromatograms were sprayed with sulfuric acid-H20-ethanol (1:1:8) rea-
gent and then strips were scanned with the Spinco model RB Analytr9l 
using the 550 mµ, filter, B-2 cam and a 1.5 mm slit .width (5). Gas 
chromatographic methods for quantitative analysis of chlorpromazine meta-
bolities in human urine, were developed by Johnson et,!±.• (127) and 
Driscoll & al. (128,129). Curry and Brodie (130) reported a method for 
estimation of nanogram quantities of CP in plasma using gas-liquid chro-
matog:raphy with an electron-capture detector, Using a combination of 
-11 gas chromatography and mass spectrometry by which 1 x 10 gram or less 
can.be separated and analyzed, Holmstedt discovered the first chlorpro-
mazine metabolite in human blood (131), Recently Ziegler & al, (61) 
determined CP-N-oxidation, on the basis of NADPH oxidation, by measuring 
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a decrease at 340 mµ. 
In.Vitro Studies on Chlorpromazine Metabolism 
It has been deTQ.onstrated that the demethylation of.chlorpromazine 
takes place.in.vivo inthe rat, using labelled chlorpromazine (N-methyl-
14c), by the_o+al or intravenous route. In this experiment the methyl· 
14 group of chlorpromazine was oxidized to carbon dioxide.- C (132). 
Later Young~ al. (133) also demonstrated that this N-demethylation 
takes place in vitro in.rat and rabbit liver homogenates. Ross !E.al .. 
(134) have studied the metabolism of 14c - or 35s-labelled chlorproma-
zine in rat and rabbit liver homogenates. Metabolic products identified 
were 14co2~ 14c-labelled formaldehyde, and the N-demethyl derivat:ive of 
chlorpromazine. Gillette and Kamm (7) demonstrated conversion of chlor-
promazi:ne to chlorpromazine sulfoxide by guinea pig liver.microsomes in. 
the presence of reduced NADP and o~ygen. Shuster and Hannam (135) 
showedtwo to three fold increase in.the activity of chlorpromazine-N-
demethylase in the livers of-mice treated with chlorpromazine. Demeth-
ylation, sulfoxidation and hydroxylation of chlorpromazine was shown by 
Robinson (136) using 9000 X g supernatant fraction containing microsomal 
and soluble fraction from livers of male rats, Chlorpromazine was.con-
verted to CPSO·(trace), nor1-CP, nor2-CP, hydroxy CP, and hydroxy-nor1-
cp. CPSO was transformedto CP (trace), nor -GP was transformed to 1 
ized. Beckett and Hewick (10) and Harinath and Odell (8) sl:).owed chlor-
1 
promazine-N-oxide formation from chlorp11omazine by liver microsomes of 
r~t, mouse and dog. Further chlorpromazine-N-oxygenase from pork liver. 
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roicrosomes was solubilized, purified and then pH and temperature.char-
acteristics were studied (9).. Ziegler ~ al. (61) demonstrated oxida-
tion of chlorpromazine and a wide variet;y of ,.other drugs, using 1000 
fold purified .enzyme from pig liver. They reported a~ value of 2.6 x 
-5 10 for chlorpromazine~ on the.basis of NADPH oxidation. The metabolic 
pathways by which chlorpromazine and its metabolites are transformed in 
vitro by rat and human liver microsomal enzyme systems were studied in 
detail by Coccia and Westerfeld (137). By thin layer chromatography and 
radio chemical quantification, the following pathways have.been demon-
strated: demethylation of tertiary and secondary amine metabolites·, oxi-
dative deamination of primary amines, N-oxidation of tertiary amines, N-
oxide reduction, sulfoxidation and aromatic ring hydroxylation of non-
sulfoxidized metabolites at position 7 and to a lesser extent; at posi-. 
tion 3. Daly and Manian (138) studied the metabolism of a series of 
chlorpromazine derivatives.with a fortified preparation of rabbit liver· 
microsomes. All of the monohydroxylated derivatives underwent mono-N-
demethylation as the principal metabolic pathway. In addition, these 
hydroxychlorpromazines were shown to undergo further hydroxylation to 
form ortho-dihydroxy-chlorpromazines, which were then mono-o-methylated, 
Thus, 7-hydroxy chlorpromazine, a major metabolite of chlorpromazine, 
was.apparently converted with this system to.a mono-a-methylated 7,8-di-
hydroxy chlorpromazine, which represents a new metabolic pathway, 
CHAPTER III 
CHLORPROMAZINE-N-OXIDATION AND DEMETHYLATION 
Experimental Procedure 
Chemicals 
Chlorpromazine (CP); nor1 and nor2 CP; CPSO; nor1 and nor2 CPSO; 
CPNO and CPSONO were obtained from Smith Kline and French Laboratories 
and from Psychopharmacology Service Ceriter, National Institute.of Mental 
Health, Bethesda, Maryland. Glucose-,,6-phosphate, NADP, NADPH, nicotina-
mide and G-6-P dehydrogenase were obtained from Sigma.Chemical Co., and 
xanthine o:ddase from Mann Research Laboratories. 
Thin layer chromatogram sheets (Type.K301R2, Silicagel.without 
fluorescent indicator) were obtained from Eastman Kodak Company. Di-
ethylamine was.obtained from Matheson Coleman and Bell and ethyl acetate, 
methanol and other solvents from Fisher Scientific Companyo Ethanol was. 
obtained from U,S, Industrial Chemicals Coo, all other chemicals used 
were of reagent grade. 
Methods 
Separations of Nonpolar Chlorpromazine Metabolites by Thin Layer Chro-
matography 
Solutions of reference compounds of non-polar (non phenolic) chlor-
promazine metabolites were prepared by dissolving 1. 0 mg in LO ml of 
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95% alcohol. A mixture consisting of all the compounds (shown in the 
Table I) was also prepared. Aliquots of 25 µ.l containing 25 µg of each. 
compound were spotted on Eastman.Kodak TLC sheet (Type K301R2•Silicagel 
without fluorescent indicator) with Lang-Levy pipettes.. The chromato-
grams were developed in the three different solvent systems. 1. Ace-
tone, isopropyl alcohol, 1% ammonia (9:7:4); 2. Butanol, Acetic acid, 
Water, (88:5:7); and 3, Ethylacetate, Methanol, Diethylamine (14:4:5). 
After development (about 90 min.), the chromatogram was sprayed with a 
color development reagent consisting of H2so4 : water: 95% ethanol (1:1: 
8) (5), Nonpolar metabolites of.chlorpromazine produce pink color on 
the thin layer.chromatogram when.sprayed with the sulfuric acid reagent, 
Rf values for the reference compqunds in the different solvent systems 
were measured and recorded in Table I, 
Enzymatic Assay for Chlorpromazine-N-Oxygenase 
Assay. Syste.m for .. CP.,..N-Oxy.genase. 
The incubation mixture (135) consisted of microsomes or other frac-
tion equivalent to 500 mg fresh liver; chlorpromazine, 5 µmoles; neu-
tralized semicarbazide, 25 µmoles; nicotinamide, 50 µmoles; magnesium 
chloride, 20 µmoles; dipotassium glucose-:-6-phosphate, 25 µ.moles; NADP, 
0.8 µmole; glucose-6-phosphate dehydrogenase 2 units; O.l·M phosphate 
buffer pH 7 .4, diluted to a total volume of 6. 8 ml. This preparation 
0 was incubated in a shaking water bath at 37 for 30 minutes under an 
oxygen atmosphere. After incubation, the reaction was stopped by the 
addition of 1.1 ml of a 20% solution of ZnS04° 7H20 and 2.1 ml of satura-
ted Ba(OH)2• The resulting precipitate was removed by centr:i.fugation 
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and t;he supernatant was· used for idimtif:l.cation an<i quantitative deter-
mination .of CPNO. Since glucose-6-phosphate dehydrogenase was present· 
in.the soluble fraction, it was.not added to the homogenate or 10,000 x 
g fractions as part.of the incubation mixture. The.control consisted of. 
the liver.fraction, chlorpromazine, semicarbazide, and phosphate buffer 
diluted to 6. 8 ml. 
Separation of CPNO 
A five ml.· aliquot of the supernatant was made· alkaline by addition 
of LO ml of 10% sodium hydroxide and thEm extracted two times with 15 
ml portions of chloroform. ihe chloroform layers were removed with a 
separatory funnel, pooled and evaporated to dryness in a rotary evapora-
t;or and the residue was dissolved in 1. 0 ml of .95% alcohol. One hundred 
µ.l aliquots of the concentrates were spotted onan Eastman. Kodak thin 
layer chromatography sheet (Type K301R2, Silica gel, without fluorescent 
indicator) with Lang-,-Levy pipettes. The chromatograms were developed in 
a solvent system consisting of ethyl acet.ate: methanol: diethylamine 
(14:4:5), by an ascending technique (113). Authentic CPNO was spotted 
on .. the same sheet . for reference. After development, the chroma to gram 
was.sprayed with a color development reagent consisting of H2so4 : water: 
95% ethanol ·(1:1:8). 
Colorimetric Assay for Determination of CPNO and Formaldehyde 
Determination of·CPNO 
CPNO produces a pink color on the thin layer chromatogram when 
sprayed witll the sulfuric acid.reagent. The chromatogram section con-
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taining the.spot.(Rf value .was 0.26) was cut·into small pieces and.ex-
tracted with 3.5 ml of 50% H2so4 (139) and the1:1 allowed,.to stand for one 
hour witQ occasional shaking. The polythene support was removed and. 
then the sample was centrifuged to.remove the silia gel. The absorbancy 
of the-colored acid extracts were determined at 525 mµ; in a·Beckman 
D.U. Spectrophotometer. The control, was.used as the blank. Figure 2 · 
shows the standard curve for determination of chlorpromazine-N~oxide by 
the.colorimetric method. In general, recovery of standard through the 
complete process showed a variation of 0.017 + 0.002 O,D. ·units fqr one 
micrpgram of.CPNO per ml of solution read. 
Petermination of Formaldehyde 
Formaldeh,yde .was determined according to. method of. Nash .. (140). One 
ml of reagent (containing 15.0 gm ammonium acetate, 0.2·ml acetylacetone 
in 50 ml of water) was .. added to 4, 0 ml of deproteinized supernatant· 
(described under CP-N-oxygenase assay) and.held in a water.bath at 60°c 
for 30 minutes. The·yellow color produced, due to the.formation of 
diacetyldihydrolutidine, was read using filtet' //42 in a Klett-Summerson 
colorimeter, 
Preparation of Subcellular Liv.er Fractions 
A modified method of Schneider and Hogeboom (141) was followed in 
the preparation of Subcellular fractions. Liver tissue from the mammal~ 
ian species (rat, mouse, dog, bovine and pig) was washed in 0.25M sue-. 
40 rose.at C. Then the tissue was·gently blotted between filter papers 
and weighed .. Fifty gms of the tissue.in 25.0 ml of. 0.25 M sucrose was 




















Chlorpromazine-'N-Oxide (µg 3.5 ml final volume) 
Figure 2, Standard Curve for Determination of CPNO, 
Known amounts of reference CPNO were spotted on TLC, developed 
and eluted as described in the experimental procedure, The 
acid.extracts were read at 525 mµ. in.a Beckman.DU spectropho,,. 
tometer using one ml quartz cells. 
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homogenizel;' for,2 min, The .reslllting suspension was centl;'ifuged at 700 
x •. g for 10 minutes. Th~ precipitate was washed with 10. O ml of O. 25 M 
sucrose and. recentrifuged at 700 x g. The prec:f.pita.te · obtained (nuclear 
fraction) was suspended in 0.25 M sucrose anti: freed from large pieces· 
of .connective tissue.by filtering the suspension through four layers of 
cheesecloth. The coml>ined 700 x g supernatant-solutions were centri-
fuged for 10 min. at ·5,000 x·g. The·precipitate, after ·washing in 0.25 
M sucrose was the mitochondrial fra_ction, The 5 ,000 x · g supernatant. 
solution was further centrifuaed f~r 60 min, at ·105,000 x g. The mic-
rosomal pellet was resuspended in.0,25 M sucrose.and both this microso-
mal-suspension and the soluble fraction were recentrifuged for ?O min. 
at 105,000 x g. 
Spectrophotom.etric and Electrophoretic Procedures 
The Cary 14 recording spectrophotometer was used to determine the 
absorption spectra of · reference compounds .. and isolated metabolit•s. 
Twenty five _µg of .reference compounds were dissolved in. 3.0 ml of 95% 
ethanol. These.solutions were used against control solutions.containing 
95%,ethanol in quartz cells of 1 cm light.path, for measuring absorption 
spectrum in,the ultraviolet region. Similar amounts were spotted on 
thin layer chromatograms developed and eluted as described earlier. 
The absorption spectrums of the ·sulfuric ad,d extracts were measured 
against control .solut.ions containing 50% sulfuric acid, 
High voltage paper electrophoresis was conducted on.a Precision 
Measurements Co., Instrument to confirm CP-N-oxide formation. A 100 µ1 
sample.of reference CPNO and isolated metabolite solutions were spotted 
for:comparison on Whatman 113 nun paper. (45 cm x 56 cm). The paper was 
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dipped on both sides in 0.05 M borate solution in such a,~anner that the· 
buffer wetted all the,paper except the part of the paper near origin. 
Wetting of the paper near the origin was done.carefully by a+lowing the 
wetting to occur by capillary action. The excess of the buffer was. 
removed by carefully blotting between two sheets of filter paper avoiding 
the removal of sample from the paper. Then the paper was placed in the 
electrophoresis tank.and a voltage of 2500 volts was applied for two 
hours, The paper was removed, air dried and eiprayed with sulfuric acid 
reagent. CP-N-oxide moved towards the cathode~ The distances were 
measured for reference and isolated compounds. 
Results 
Separation of Nonpolar Chlorpromazine Metabolites 
Several solvent systems were described by other workers (3,5,125, 
126) for separation of chlorpromazine metabolites by paper chromatogra-
phy. Thin layer chromatography was used for separation of hydroxy 
chlorpromazines (3). Most_of the solvent systems developed.were.used 
for separation of groups of chlorpromazine metabolites such as sulfox-
ides, hydroxy chlorpromazines and de'!llethylated chlorpromazines. There. 
was no comprehensive method for separation of major nonpolar chlorproma-
zine metabolites by thin layer chromatography. Since absorption maxima 
for related metabolites (Table II) appear similar, it is necessary to 
separate and 9uantitatiyely determine the desired metabolite in order to· 
develop an enzymic assay. About fifteen solvent systmes described by 
other workers were tried (3,5,125,126). Three were found to be suitable 
for separation of major nonpolar CP metabolites by thin layer chromatog-
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raphy (Figure 3), A mixture conta:l.ning eight reference compounds shown. 
in Table!; presents comparative results on the.basis of Rf values of 
reference compounds in. different solvent systems. Each can, be· separated 
from this mixture. CPSO, CPSONO and nor1 CPSO were separated in solvent 
A; CP, nor1 .and nor2 CP in solvent B; CPNO, CPSONO and a mixture of nor1 
CPSO and nor2 CPSO in solvent C. This mixture of nor 1. and nor2 . CPSO 
was·eluted into methanol from an unsprayed chromatogram and respotted 
and developed in solvent A for separation of nor1 and nor2 CPSO •. · Thus, 
all the e;ght.nonpolar metabolites can be.separated and determined 
quantitatively from enzyme incubated mixture, as reported in experimen.,-
tal for chlorpromazine-N-oxide. Solvent C was routinely used to separ-
.ate CPNO from the assay system, 
Absorption maximum· (t..max) for certain related metabolites in the 
ultraviolet region were shown in Table II. Twenty-five µg of chlorpro-
mazine and other compounds in.3.0 ml of 95% ethanol were used for re-
cording µlt.raviolet absorption spectra, A similar amount was spotted on 
TLC and developed in solvent C (shown in Table I). After spraying with 
sulfuric acid reagent, the pink area of each of the compounds on the 
TLC sheet were eluted with aqueous (50%) sulfuric acid, These acid ex-
tracts were used for recording the ultraviolet absorption spectra. 
From Table II it may be seen that CP and CPlefO haye absorption maxima at. 
256 mµ, whereas for CPSONO it is at 239, 276 and 300 mµ. Sulfuric 
acid extracts of ,.all the three compounds. have. >,,max at 269 and 277 mµ,. 
In addition to chlorpromazine-N-oxide, an additional metabolite with a 
closely related Rf value in solvent C (shown in Table I) was obtained 
from incubatiot:1 mixtures, An.or1;1nge color was developed when the TLC 
Figure 3, Separation of Nonpolar Chlorpromazine 
Metabolites by Thin Layer Chromatography. 
Developing solvent systems and spraying reagent 
were as described in Table I. 1 = CP, 2 = nor1 
CP, 3 = nor2 CP, 4 = CPSO, 5 = nor1 CPSO, 6 = 
no1·2 CPSO, 7 = CPNO, 8 = CPNOSO. Solvent C was 
routinely used for isolation of CPNO, 
A. 














SEPARATION OF NONPOLAR CHLORPROMAZINE METABOLITES 
Rf.Values. 
Compound. Solvent Al Solvent B2 Solvent c3 
Chlorpromaiine (CP) 0.79 0.31 0.94 
nor1 CP 0.79 0.59 0.94 
nor 2 CP 0;79 0.70 0.94 
CPSO 0.56 0.17 . 0.94 
nor1 CPSO· 0.27 0.17 0.84 
nor2 CPSO 0.79 0.44 0.84 
CPNO 0.79 0.44 0.49 
CPS ONO 0.40 · 0.17 0.18 
l· .. 
Acetone, Isopropyl alcohol, 1% Ammonium h:yclro;idde · (9: 7 : 4) • 
2 Butanol, Acetic acid, Water (88:5:7) 
3 Ethyl acetate, Methanol, . Diethyl amine · (14: 4: 5) • 









ABSORPTION MAXIMA OF CHLORPROMAZINE 
AND-RELATED METABOLITES 
Solvent 



















plate was $prayed with the sulfuric acid spray reagent. This acid ex-,, 
tract·had an absorption maximum at,273.5 mµ.. The ultraviolet absorp-
tion spectra of this metabolite shows that it.is ·different from CPNO and 
CPSONO. 
Chromatographic and Electrophoretic Identifica~ion 
of Chlorpromazine-N-Oxide · 
In the separation and elution of CPNO from the incubation mixture, 
2.0 ml of the concentrate was spotted on the.chromatogram sheet in a 
horizontal ·line. After development in solvent C (shQwn in Table I), 
part of the chromatogram was sprayed, A corresponding section of.the 
chromatogram from the unsprayed portion of.the chromatogram was cut into 
small pieces.and extracted with 25.0 ml methanol. The methanol layer 
wa~ removed after centrifugation, evaporated to dryness in.a rotary 
evaporator and taken 1,1p in 2.0 ml of 95% alcohol,. Aliquots of 100 µ.l 
ax-e.spotted along with authentic CPNO. and developed in different solvent 
systems (see ·Table III) to confirm the identification of CPNO. It ,may 
be seen that reference .CPNO and aproduct .from the incubation-mixture 
have·the same Rf.value in 4 solvent.systems with a thin layer.chromate-,, 
graphic technique, 
Figure.4 shows the ultravi9let absorption spectra of CP, refer-
ence.CPNOand CPNO produced by action of mouse'liver mictosomes on CP. 
'l'he · reference CPNO and the tnicro.somal ·. metabolit~·.: have. essentially the 
same spectra •. High voltage electrophoresis of reference.and.microsomal 
CPNO shows·a migration of 7 and 7.~ cm. respectively, under the condi-
tions.described in experimental, A CP reference migrated O cm under. 
the same conditions. Fr~m these data it may.be concluded CP was. con-
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TABLE III 
CHROMATOGRAPHIC IDENTIFICATION OF CHLORPROMAZINE-N-OXIDE 
Thin Layer Solvent Systeml Reference Microsomal CPNO Metabolite 
1. Ethylacetate, methanol, diethylamine 0.27 0.26 
(14:4:5) 
2. Acetone, diethylamine (9:1) on base line on base line 
3. Acetone, isopropanol, 1% NH40H (9:7:4) 0.81 0.82 
4. nButanol, acetic acid, water (50:12:SO/ 0.72 0.74 
1Eastman Kodak Thin Layer Chromatographic Sheet ('l'ype.K301R2, 
Silica gel.on polythene backing). 












Figure 4, Absorption Spectra of Chlorpromazine and the Met-
abolite Chlorproma·z i.ne-N-oxide. 
One cm light path, fused quartz cel~s were used with 25 µg 
of the reference compound in 3.0 ml of 95% ethanol, The ul-
traviolet absorption spectra were determined in a Cary 14 
recording spec trophotome.ter, 
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verted .· to CPNO by ·a mouse· 1:l,ver microsomal preparation. This establish-
ed the.earlier identification of CPN:O in the.urine of dog (6)~ 
Formation of Chlorpron:iazine-N-Oxide 
by Subcellular Liver Fractions 
Table IV shows an.example of the .distribution of CP-N-oxygenase 
activity in cellula;- fractions from mouse liver. In general, higher 
activities were observed in the microsomal.preparations. This agrees 
with the.general concept that drug metabolizing enzytnes are located in 
microsomes, 
Species Dif(erences in N-Oxidation and. 
Demethylation of Chlorpromazine 
Table V shows .the relative activities of CP-N-oxygenase and.demethy-
lase in the liver tissuelj:I of mouse, rat, dog, p;Lg and bovine. CP-N-oxy""' 
genase activity at the microsomal.level in different mammalian species 
shows the fallowing pattern: dog = mouse >pig> rat> bovine. Dog and . 
man were shown. to excrete CPNO as an u:dnary product. The li.ver -micro-
somal demethylase activities of dog, mouse and rat were similar, whereas 
pig showed. decreased demethylase activity. 
Ta~le VI presents data obtained with the mouse.liver fractions for 
the formation of CPNO and formaldehyde. The demethylase reaction appar-
ently.proceeds at'a slower rate than the CPNO reaction. This evidence 
alone would not exclude CPNO as an intermediate in demethylation as both 
compounds are.found as metabolic products in.the urine. 
Table IV and VI show less N-oxide formation by homogenates than·by 
microsomes. Possible explanations fot these data are as follows: 1) 
TABLE IV 
FORMATION OF CHLORPROMAZINE-N-OXIDE BY SUB-
CELLULAR LIVERFRACTIONS FROM THE MOUSE-
CPNO Formed 
µmoles CPNO/gm liver/hr. -
Liver Fraction Mouse 1 Mouse 2 Mouse 
Homogenate 4.76 0.10 0.20 
Nucle:i,. (700 x g) 3.50 0.27 0.36 
Mitochondria (5000 x g) 3.78 o.oo 0.45 
r.:Iicrosomes (5000-105,©00 x-g) 6.65 2.16 2.79 


















SPECIES DIFFERENCES IN N.,.QXIDATION !ND DEMETHYLATION 
OF CHLORPROMAZINE BY LIVER MICROSDMES- · 
CP!-fO Formed, Formaldehyde.Formed 
_µPloles/gm liver/hro' µ.moles/ gm liver/hr. 
2,70 1,13 













CHLORPROMAZINE-N-OXIDE AND FORMALDEHYDE FORMATION 
FROM CHLORPROMAZINE BY MOUSE LIVER FRACTIONS 
CPNO Formed Formaldehyde Formed 
µ.moles I gnl 1:1. ver/hr. µ.moles/gm·liver/hr. 
Fraction Mouse 1 Mouse 21 Mouse 1 Mouse 21 
Homogenate 0.81 1.49 1. 76 1. 97 
Supernatant.(10,000 x g) 3.2 4 .• 46 1.58 2.02 
Microsomes 4.5 6.48 0.60 0.76 
1c3H strain mouse used in this experiment. 
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the CPN-oxide formed.by microsomes.in the homogenate may·have·been de~ 
methylated ·(N.-demethylase was found.in the mitochondr:1,.al and.light mito-
chondrial fractions), 2) CP-N-ox:l,de maybe reduced by xanthine oxidase 
(as ·a source of oxygen) (142) and 3) some inhibitor may be present· in. 
the homogenate. 
RequiremeIJ.t for.NADPH for Demethylation of 
Chlorpromazine and Chlorpromazine-N-Oxide 
The·NADPH requirement of the CP-N-oxygenase is established by·the 
data shown in Table VII; CP was ·not converted to the N-oxide and was. 
not demethylated to an appreciable extent in the absence of NADPH. 
Z:1,.egler ~ !!.· (146) reported tha.t NADPH was ·not required for oxidative 
demethylation of N,N-d:l,methylaniline-N-oxide by pig liver i;nicrosomes. 
However, from this experiment·NADPH seems to be essential for N-oxide 
formation from CP and for oxidative demethylatiori of.CP or CPNO. It has 
been ob,served that hydrogen .peroxide may.· be utilized by. :i;ion ... specific 
enzymes in microsomes.to catalyze various drug reactions (18). Hydrogen 
peroxide co\.\ld not substitute fo:i:- NADPFl in the·N-oxidat:ton of CP. This 
is in agreement with the obs.ervation made by Cooper and Brodie (143) in 
the oxidation of hexobarbital. 
It _was also observed that the demethylation of CP wa,s ·. greater than 
that of CPNO in the presence of NADPH. This would indicate that CPNO is 
not.an-intermediate-in oxidative demethylat;ion of-CP, 
Ability of Xanthine Oxidase t;o Catalyze 
N-Oxidation of Chlorpromazine 
Oxidation of nicotinamide to nicotinamide-N-oxide has been demon-
TABLE VII 
REQUIREMENT FOR NADPH OF MOUSE LIVER MICROSOMES1 
IN THE DEMETHYLATION OF CHLORPROMAZINE 
AND CHLORPROMAZINE-N~OXIDE 
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CP + NAD~H Generating System 
(Complete) 




CP + Hydrogen Peroxide 
CP + Hydrogen Peroxide 
CPNO + NADPH Generating System 




µ.moles/gm liver/hr~ IJ,moles/gm liver/hro 
2.16 1.85 









1All experiments were not conducted with the same microsomal pre~ 
paration. Five moles of CPNO were used in the la~t 4 assays in place 
of CP; 
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strated in vitro with use of liver microsomes from rats, mice and 
rabbits (144), Murray and Chaykin (142) reported that xanthine oxidase 
catalyzed the transfer"of 180 from nicotinamide lBO-N-oxide to xanthine 
in.the course of the formation of uric acid. Further, they suggested a 
possibility that heterocyclic N-oxides may be capable of acting as gen~ 
eral biological oxygenating agents. Studies were made on commercially 
available xanthine oxidase (from Mann) to see whether this enzyme.can 
catalyze N-oxidation of chlorpromazine or utilize CP-N-oxide for oxida-
tion of xanthine under anaerobic conditions. In the presence or absence 
of NADPH generating system, xanthine oxidase did not produce any signi-
ficant amount of CP-N-oxide .. Further xanthine was not oxidized to uric 
acid (no detectable increase in absorption at 295 nµ) in the presence 
of CP-N-oxide, with this enzyme under anaerobic conditions, However, 
when xanthine oxidase was .incubated with chlorpromazineand Tris chloride 
buffer pH 8.0, a very small amount of a purple metabolite (when sprayed 
with sulfuric acid reagent) was infrequently observed indicating a hy-
droxylated metabolite of chlorpromazine. 
CHAPTER IV 
PARTIAL PURIFICATION AND PROPERTIES OF CHLQR .... 
PROMAZINE-N-OXYGENASE FROM PIG LIVER 
Experimental Procedure 
Chepticals 
Calcium phosphate gel was prepared accordiri.g to the method of Kei-
lin and Hartree (145). DEAE cellulose, CM cellulose, alumina Cy, prota-
mine sulfate and PCMB were obtained from Sigma Chemical Co. Agarose gel 
(10%) and thyroglobulin were obtained from Mann Research Laboratories. 
Biq-gel from Bio-Rad Laboratories and catalse from Worthington Biochemi-
cal Corporation. EDTA and sodium dithionite were obtained from J.T. 
Baker Chemical Co., and sodium azide from Matheson Coleman and Bell. 
Potassium cyanide and ammonium sulfate were obtained from Mallinckrodt 
Chemical works and carbon monoxide gas from Matheson Co., Inc. All· 
other chemicals used were the same as described in Chapter III. Fresh 
pig liver tissue was obtained from Ralph's Packing Company, Perkins, 
Oklahoma. 
Methods 
Enzymatic Assay for Chlorpromazine-N-Oxygenase 
The procedure was the.same as clescribed in Chapter III .with a slight 
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modification in the assay system and conditions. This consisted of 
enzyme protein 1-2 mg; chlorpromazine, 50 µmoles; glucose-6-phosphate 
25 µmoles; NADP, 0.9 µmole; nicotinamide, 100 µmoles; MgC12, 2Q µmoles; 
G-6-P dehydrogenase, 2 units; Tris chloride buffe~ pH 8.5, 200 µmoles 
and dilution with water up to 5.0 ml. With certain inhibitors instead 
of NADPH generating system, 6 µmoles of NADPH were added. The control 
contained heat inactivated enzyme. These 'preparations were incubated in 
0 open erlenmeyer fasks in a metabolic shaker at 37 for 30 minutes. 
Enzymatic Assay for N,N-Dimethylaniline Oxygenase 
The incubation mixture was similar to that of chlorpromazine-N-oxy-
genase, with the following modifications. In this assay N,N-dimethylan-
iline 10-40 µmoles and potassium phosphate buffer pH 7.5 (200 µmoles) 
were used. 0 Incubation was conducted in open erlenmeyer flasks at 37 C 
for 15 minutes. N,N-dimethylaniline-N-oxide was determined according 
to the method of Ziegler~ al. (146). Each reaction mixture was depro-
teinized with 0.3 ml of 6N perchloric acid. The deproteinized superna-
tant solution was adjusted to pH 9.4 with 10% sodium hydroxide and ex-
tracted three times with diethylether to remove all of N,N-dimethylani-
line. After extraction, the pH of the aqueous solution was adjusted to 
2.5 with 3M trichloroacetic acid and 0.1 M sodium nitrite solution was 
added to attain a final concentration of 0.009 M of nitrite. This solu-
tion was then heated for 5 minutes at 60°c, and then read at 420 mµ 
against water blank. The assay is based on the observation that at pH 
2.5 the N-oxide is quantitatively reduced by nitrous acid to N,N-dimethy-
!aniline which readily forms the yellow p-nitroso derivative. 
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Enzymatic Assay for Methanol Oxidase 
The assay mixture was similar to that of N,N-dimethylaniline oxi-
dase; except that the substrate consisted of 250 µ.moles of methanol in-
stead of N,N-dimethylaniline. The deproteinized solution was used for 
determination of formaldehyde as descril:>ed in Chapter III,, 
Spectrophotometric Measurement of ,Cytochrome P-450 
The carbon monoxii;ie difference·spectra of liver.microsomes·and pro-
tamine sulfate·supernatant were measured according to t~e method of 
Omura and Sato (l47). Difference spectra were measured in a Cary model 
14 spectrophotometer with cuvettes of l~cm optical path, Microsomal and 
protamine sulfate.supernatant preparat;i.ons, usually containing 1.5 mg of . 
. J 
protei.n per ml of 0.1 M phosphate buffer (pH 7.0), were placed in both 
the S$mple and reference eel.ls. Reduction of samples was effected with 
a few milligrams of solid sodium dithionite (Na2s2o4). After recording 
the base line, carbon monoxide was carefully bubbled through the sample 
for about.30 seconds which was sufficient to saturate the sample with 
the gas, The difference spectrum was measured after several minutes, 
All spectrophotometric measurements were made at room temperature. 
Purification of Chlorpromazine-N-Oxygenase from Pork Liver 
Protein was determined by the method of Lowry ~ al. (148). Unless. 
0 otherwise stated all procedures were carried out at 0-4 c. 
p,,:eparation of Pork Liver .Microsomes · 
Liver microsomes were prepared following the procedure of Gillette 
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et al. (18). The livers were collected on the kill floor of the slaugh-
ter house within 10-15 minutes after the animals.had been killed, These 
organs were immediately cut into slices about one inch thickness and 
placed into large.polyethylene bags which were stacked into an ice chest 
between layers of crushed ice.. The chilled tissue .slices were washed 
twice with approximately equal.volumes qf 1,15 percent KCl solution and 
homogenized.for 2 minutes in a waring blendor at low speed, with three 
volumes of 1.15 percent KCl solution. The homogenate was centrifuged at .. 
10,000 x g for thirty minutes.to remove.unbroken cells, nuclei and mito-
chondria, The supernatant fraction, containing microsomes and soluble 
supernatant, was filtered through,glasswool and centrifuged in a Spinco 
preparative ultrac::entrifuge at.85,000 x g for one hour, The microsomes. 
were separated, washed once with the KCl solution and recentrifuged for 
90 min. The microsomes were then suspendep in KCl solution and stored 
0 at -20 I 
Solubilization of. Microsomes 
Initial attempts using trypsin were unsuecessful. Then microsomes 
were solubilized according to the method of Ziegler et al. (60). Micro-
somal suspensions in 0,2M glycine buffer pH 8.9 were subjected to.sonic 
vibration with a Bronson 20KC sonifier, model No, 8125 set at position 8, 
for 75 sec. at ,4 intervals. Triton X-100 was added to a final concen-,, 
tration of 0.5 mg detergent per mg protein and then held at 0° for 15 
minutes. The suspension was.then centrifuged at 105,000 x g for six 
hours and the sonication supernatant was collected~ 
Further Purification of Chlorpromazine-N-Oxygenase 
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The enzyme from 800 ml of .sonication supernatant was precipitated 
by the addition of solid ammonium sulfate (194.5g) to approximately 40% 
saturation, allowed to stand for 20 minutes and then centrifuged at 27, 
750 x g for 15 minutes. The precipitate was suspended into 240 ml of 
0.025 M phosphate buffer. At this stage the preparation can be stored 
at -20°c for several weeks with no significant loss in.CP-N-oxygenase 
activity. The 0-40 fraction was thel'l dial,yzed for four.hours against. 
10 liters of 0.01 ·M phosphate buffer. The dialyzed fraction was further 
treated with neutralized protamine sulfate solution (0.2 ml of 2% pro-
tamine sulfate solution was added for each ml of dialyzed fraction), 
allowed to stand for 20 minutes and then centrifuged at 27,750 x g for 
10 minutes. The-supernatant.obtained was labelled as protamine sulfate 
supernatant. 
Addition of either Alumina Cy or calcium phosphate gel.at different 
concentrations to protamine sulfate supernatant did not yield further 
2 
purification. DEAE cellulose column (2.5 x,26 cm) chromatography at. 
different pH (7,6, 8,0, 8.5, and 8.9) and CM cellulose column chromate-
graphy (at pH 8.0) were not successful in increasing the purificationo. 
This enzyme was excluded along with blue dextran 2;000 on Sephadex.G-75 
2 . 2 
(50 x 1 cm) (Figure 5) and 10% Agarose gel (1 x 40 cm) (Figure 6) coh 
umns which were previously equilibrated with 2M glycine buffer pH 8.9· 
anq. 0.025 M phosphate buffer pH 8 respectively and then subsequently 
eluted .with the same buffers. This indicates that the enzyme has a mo-
lecular weight around 400,000. 
Bio-Gel A-5M, 200-400 mesh (exclusion limit, 5 x ;1.0 6) was suspended 
in 0,05 M phosphate buffer, pH 8 containing ,lM KCl and all entrained-
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Figure 5, Elution of CP-N-Oxygenase From a Sephadex 
G-75 Column. 
3.0 ml of 0-40 enzyme fraction (60 mg protein), blue 
dextran and 120 mg sucrose were placed on the.column, 
Three ml fractions were collected. Flow rate was 8 
ml/hour. After measuring the absorbancy at 280 mp, , 
fractions 9~15, 16~20, 21..:11726, 27~30 and 31-=?34 
were pooled and 2.0 ml of each was used to determine 
CP-N-oxygenase activity as descri~ed under experimen-
tal procedure. All the activity was found between 
fractions 9..a,,20. Blue dextran was also observed be-
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Figure 6. Elution of CP-N-Oxygenase from an Aga-
rose-Gel ·(10%) Column, 
3,0 ml protamine sulfate supernatant• (8 mg pro-
tein), and blue dextran were placed on the column •. 
3.5 ml fractions were collected. Flow rate was 
about.9.0 ml/hour. After reading the absorbancy 
at 280 mµ. , fractions 6~10, 11...+14 and 26,27 were 
pooled and 2,0 ml of each was used to determine 
CP-N-oxygenase activity as described under experi-
mental procedure. About 50% of the activity was 
found.between fractions.6~10. No activity was 
observed in other·, fractions. Blue dextran was .. 
distributed between fractions ~12 and maximum 
was observed in 7th fraction. 
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0 until bubbling ceases. The slurry was allowed tQ stand at 4 C for one 
2 day with decantation of the buff.er twice. A column (4.5 x 67 cm) was 
packed with the prepared Bio-Gel and equilibrated for.two or three days. 
The column was calibrated using thyroglobulin (molecular weight 670,000) 
and catalase (molecular weight; 244,000). Eight mg of thyroglobulin, 
150 µl of catalase and 80 mg of sucrose were dissolved in 2.0 ml of 0.05 
M phosphate buffer, pH 8 containing 0.1 M KCl and placed on the column 
and eluted with the same buffer. The column was.washed for t\vo days. 
and then 3.0 ml of protamine sulfate supernatant fraction containing 
about .. ;LS mg of protein and 90 mg of sucrose was, placed, on. the columno · 
Preseiure head was 40 ems and rate of flow was 10 ~1 per hour. Six ml. 
fractions were' collected and elution was with O.OSM phosphate buffer, 
pH 8 containing 0.1 M KCl, 
Protein was measured at 280 ~µ in Beckman DU spectrophotometer, 
Two ml of eluant was used to determine catlase activity by DB spectro-
photometer. Sample cell contained 1,0 ml of H2o2 solution containing 
0.3 ml of 30% H2o2 in 100 ml of 0,05 M phosphate buffer, pH 7 and 2 •. 0 ml 
of each fraction from column. Reference cell contained water instead of 
H202 solution, Catalase activity was measured by following decrease at 
240 mµ for fifty seconds (149). 
Fract;Lons.48-51, 81-84 and 109-113 were pooled, lyophilized and the 
residues were suspended in 2.0 ml of water (Figure.7). One ml of each 
was used for determination of CP-N-oxygenase activity, as described 
under experimental procedure. The enzyme activity appears to be dis-
tributed between 48 - 51 and 109 - 113 fractions; about 13% of the ac-
tivity between 48-51 and 48% of the activity, between 109-113 fractions, 
Figure 7. Elution of Thyroglobulin, Catalase and 
CP-N-Oxygenase From a Bio-Gel A-Sm Col-
umn. 
--~ = absorbance at 280 mµ. , 
~ = CP-N-oxygenase activity, 










































Fi-om this pattern, molecular weight of the enzyme could not be decided. 
The concentration.of CPNO was too low for determination by colorimetry. 
Therefore, the acid extracts were read at 277 mµ., absorption maximum for 
sulfuric acid extract of CPNO as.shown in Table·II. CP-N-oxygenase in 
the.fractions 109-113 showed abo1,1t 10 fold increa,e in. purification .com-
pared to protamine sulfate supernatant; whereas · thEt enzyme between 48-51 
fractions.showed no purification. However, more sensitive techniques, 
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such as using S labelled chlorpromazine, wil:,l be beneficial in .further 
:purification and stud.ies on mechallism of· cp.:..N-oxygenase! 
Results 
Pu:i.ificatio~ of Chlo:rpromazine-N-Oxygenase .. 
A summary of purification steps are shown in Table VIII., The purb 
fielii enzyme from pig liver microsomes shows an.18 fold purification from 
microsomes,or about 900 fold frotn liver ho~ogenate, with no loss.in 
yield. Protamine sulfate supernatati.t.was used for studying the proper-
ties of this enzyme. 
Requirement$ of Chlorpl;'omazine.:..N-Oxygenase. 
Table IX shows.certain.requirements of chlorpromazine-N:-oxygenase" 
The incubi:ition mixture.as de$ctibed in the experimental.procedure sec, 
tion, and othe.r reaction mixtures omitting substn.te; NADPH generating 
system, buffers were incubated with 0.4 ml of the.enzyme, purified 
0 through the protamine sulfate step at 37 C for thirty minutes. From 
th~ table the NADPH·generating system appears to be essential for maxi-
mum enzyme activity. 
TABLE VIII 
PURIFICATION OF CHLORPROMAZINE-N~OXYGENASE 
Total Total Total Percent Specific 
Volume Proteinl Units2 Yield Activity2 
ml mg mµmoles/min mµ.molesb.n.g.:protein/min 
Homogenate 4000 156000 5440 --- .035 
Microsomes 1000 23200 40800 100 1. 76 
Sonication Supernatant 800 11840 30000 73.6 2.54 
40% Ammonium Sulfate Precipitate 240 3660 72480 177 19 • .8 
Protamine Sulfate Supernatant 276 1440 47300 116 32.8 
1towry Protein Determination~ 










REQUIREMENTS OF CHLQRPORMAZINE-N-OXYGEN4SE 
Composition of Reaction Medium 
l Complete. 
Minus Chlorpromazine 
Minus NADPH Generating System 
Minus Buffer 









1rncubation mixture contained a final concentration of.chlorproma-
zine, 10 mM; glucose-6-phosphate, SmM; NADP, 0.2mM; nicotinamide, 20 mM; 
Mgc12, 4mM; 2 units of gl,ucose-6-phosph~te c;lehydrogenase; Tris chloride 
buffer, pH 8.5, 40mM; and 1.5 mg of enzyme protein. 
2 Enzyme.was.kept in boiling water bath for 5 minutes before.addi"'." 
tion to the assay system. 
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Enzyme Activity Versus Protein Concentration 
The· assay mixture was.incubated with various.levels of enzyme puri-
o f:i,ed through the protamine sulfate step, for thirty minutes at.37 C. 
The reaction is linear with protein concentration up to.about 1.8 mg of 
protein per 5.0 ml total.volume (Figure 8). Normal assays, therefore, 
contained.enough enzyme.to produce 10 to 30 mµ.moles chlorpromazine-N.,... 
oxide per minute. 
Time Course of Reaction 
The reaction mixture was incubated with 0.3 ml of enzyme, purified 
through protamine sulfate step at 37°, and the.reaction stopped at 
selected time intervals by the addition of zinc su;l.fate.and barium hy-
droxide as described in,the experimental procedure. F:;l..gure 9, shows 
the time course of the reaction. Routine assays were conducted for 
thirty minutes to obtain suffi.cient chloromazine-N-oxide for determina-
tion by thin layer chromatography. 
Effect of Temperature on the Enzyme Activity 
The reaction mixture was incubated with 0,3 ml of enzyme, purified 
through-the protamine sulfate step at the.temperatures indicated (Figure 
10) for thirty minutes and then assayed for CPNO formed. Temperature 
was optimum.between 30-37°C and loses about 70% of the activity at 45°Co 
Effect of pll on the Enzyme Activity 
The reaction mixture was incubated with 0.3 ml of enzyme,.purified 
through the protamine s1,1lfate step at.different pH values, using acetate, 
t:l 



















mg protein/5.0 ml of assay mixture 
Figure.a.· Enzyme,Activity Versus·Protein Concentration. 
Incubation mixtures containing a final conce.ntration: chlor:.... 
promazine, 10~; glucose-6-.phosphate, 5 tllM; N.ADP, 0.2 mM; 
nicotinamide, 20 mM; MgC12 ,_ 4 mM; 2-units of glucose-6-phos-· 
phate dehydrogenase; Tris chloride buffer, pH 8,5, 40 mM; 
and various levels of enzyme purified through the•piotamine 
sulfate step, were incu\)ated at , .37° for thirty minute!:) and 
then assayed for the amount of ;C,NO formed~ 
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Ftgure 9. Time Course of Reaction. 
Incubation mixtures as described under Figure 
8, were incubated with 1.5 mg of enzyme protein 
preparation in a final volume of 5.0 ml for the. 
time intervals indicated at 37° and then the 
amount of CPNO formed we.s determined. 
41 = Freshly prepared protamine sulfate super-
natant. 
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Figure 10, Effect: of Temperatut'e on ·the 
Enzyme Activity. 
Assay mixtures·as.described under Figure 8, · 
were incubated with one mg of enzyme .. pro-
tein preparation at temperatures indicated 
for thirty minutes and then assayed for the 
amount of CPNO formed. 
4t = Freshly prepared protamine sulfate 
supernatant. 
• = Preparation stored at -20° for ap-
proximately 3 weeks. 
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potassium phosphate, Tris chloride and sodium glycinate (Figure 11), 
From the pH curve, optimum pH was at 8.5. 
Velocity Versus Chlorpromazine Concentration 
In this experiment 0.2 ml of enzyme was incubated for thirty min~ 
utes at 37°C with increasing concentrations of chlorpromazine (Figures 
12 and 13), A graphical determination of the Michaelis constant for 
-3 chlorpromazine gave~ Km value of 3.57 x 10 M, · 
Competitive Inhibition of Chlorpromazine on 
the N-Oxidation of N,N-Dimethylaniline 
The reaction mixture for N,N-dimethylaniline oxygenase.as described 
in the experimental procedure was.incubated with 0.3 ml of the enzyme 
and with increasing concentration of N,N-dimethylaniline in the presence 
-3 . 0 (2 x 10 M) and in the absence of chlorpromazine, at 37 for 15 minutes. 
Then N,N-dimethylaniline N-oxide was determined as already described. 
Chlorpromazine at the concentration of 2 x l0-3M shows competitive inhi-
bition (Figure 14) indicating fairly broad specificity of this enzyme. 
Effei;t of Inhibitors. on.Chlorpromazine-N .... oxygenase· 
Incubation mixtures as described in the.experimental procedure were 
incubated with 0.3 ml of the enzyme in the presence of certain inhibi-
tors'shown in Table X, In the case of PCMB, EDTA anq iodoacetamide, 6 
µmoles of reducedNADP were added instead of N~PH generating system 
along with a control. Little or no inhibition by cyanide and azide in-
dicates that hemoprotein is not involved in this N-oxidation reaction 
mechanism but a slight inhibition by EDTA indicates a metal involvement. 




















Figure 11. Effect of pH on the Enzyme Activity. 
Reaction mixtures as described under.Figure 8, using 
acetate, phosphate, Tris chloride and glycine 'l)uffers 
with diHerent pH values, were incubated at 37° for . 
thirty minutes with 1.5 mg of enzyme protein and the 
amount of CPNO formed was .determined as described under 
experimental procedures. 
~ = · Acetate,_&:.: Potassium phosphate, e = Tris. 
chloride, • = Sodium glycinate. 
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Figtire.12. Velocity of Reaction Versus Chlorpro-
mazine Concentration. 
Incubation mixture as described under Figure 8, 
with various concentration leve;).s of chlorproma-
zine were incubated with 1.0 mg of enzyme protein 
for.thirty minutes at 370 and then assayed for 
the amount.of CPNO formed, 
Figure 13, Lineweaver-Burk Plot of Reaction; 
Reciprocal Veloc;!.ty Versus Chlor~ 
promazine Concentration. 
Same conditions as Figure 12. 
i:: 
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Figur;e .· 14. Linew~avet-Butk Plots suggesting tl:ie Coi:p.-
petitive Inhibition of Chlorpromazine on· 
the N-o:ddation of N,N-Dimethylaniline • 
.A= ~CP; ..... +2 x 10-3M CP 
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. SKF ... 525A does 'not show any. significant inhibition of N~ox;idation. Inhi-
bition by PCMB and iodoacetamide indica.tes the,sulfhydryl nature,of this· 
enzyme. 
Effect of Inhibitors on Methanol Oxidation 
Reaction mixture· for methanol o:ddase as ·described in the , experi-
mental procedure·was incubat,d with 0.3 ml c,f enzyme in the.presence of 
certain inhibitors shown.in TableXI. At the encl of.the react;ion, for-
maldehyde was dete:i;:mined as.descr;f.bed in the methods. A comparison of 
the effects of inhibitors on chlorpromazine and methanol ox;f.dation by 
the enzyme,is shown in Table XI. Methanol oxidation is,inhibited up to 
·50-70 percent by cyanide and azide but no sigµ.ificant·inhibition on 
chlorprorilazine-N-oxidation, indicating that·~ethanol oxidase.constitutes 
a separate enzyme system from chlorp.romaz;l.,;u;a-N-oxygenase. 
Carbon.Monoxide Difference·Spectra 
Car~on monoxide difference spectra.of·pig liver microsomes.were. 
measured.as described in experimental procedure (Figure 15). Table XII 
shows the absorbance inc:rement in a co difference spectru,m at 450 Illµ and. 
420 mµ, in·microso~es.and protamine sulfate·supernatant. As the enzyme 
is purified, instead of an increase in the ratio of cytochrome to pro~ 
tein, P-450 is decreased followed by an increase in P-420. This indi-
c:;ates that P-450 is partly,solubilized during purification p:i;:ocedure·and 




EFli'ECT OF INHIBITORS ON CHJ;.ORPROMAZINE-N-OXYGENASE ACTlVIl'Y 
CPNO 
Addition Cone, Formed Inhibition 
(M) mµmol'es/min. % 
None 26.6 
Azide 10-3 29.3 0 
PCMBl. 10-3 3;2 84.4 
KCN 10-3 26.2 1.5 
SKF 525 A 10-3 ' 25;4 4.5 
EDTA1 10-3 18.2 9.9 
Iodoacetamide1 10-3 14.8 26.8 
None 1 20.2 
1TPNH (6µmoles) was added instead of TPNH generating system. 
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TABLE XI. 
EFFECT OF INHIBl;TORS ON CHLORPROMAZINE AND METHANOL OXIDATION 
CP-N.-Oxidation ·. Meth$nol. Oxidation 
CPNO HCHO 
AqditioI). Cone. Formed. Inhibition Formed Inhibition 
(M) mµ,moles/min % mµ,moleiii/min. % 
None 26.6 4.65 
KCN 10-3M 26.2· 2 2.1 54.8 
Azide 10-3M 29,3 0 1.2 74.2 
Protamine sulfate 
SQpernatant 
Baseline Sample plus CO ____ ._ ______________ _._ _____ ..._  _.__ ... __ 
540 520 500 480 460 4-10 420 
Wavelength (m...,) 
Figure 15. Carbon Monoxid~ Difference Spectra. 
Carbon monoxide difference spectra were measured as described 
witl,. a Cary 14 recording spectrophotometer. Microsomal. and 
protarnine sulfate .supernatant preparations contained 1. 5 mg 











Absorbance increment in 
CO.difference spectrum 
.450 nµ 420 mµ 
mµ.moles/mg protein/min AA/mg protein AA/mg protein 
1.76 o.oo~ .005 
32.8 Q.007 .012 
CB.APTER V 
DISCUSSION 
A large amount of research has been conducted on the detection and 
estimation of chlorpromazine metabolites but a satisfactory comprehen-
sive systematic procedure which can.be used routinely in enzymatic 
studies on ch1orpromazine metabolism has still not been described. Phen-
olic metabolites of chlorpromazine yield a purple color whereas nonpheno-
lic metabol,ites produce a pink color when treated with sulfuric acid 
spray reagent. For enzymatic studies, the spe~ific metabolite must be 
separated from all othe.r metabolites and chlorpromazine and determined 
quantitatively. Table I shows a separation of seven nonpolar chlorpro-
mazine metabolites and chlorpromazine, in three solvent systems, by thin 
layer chromatography. CP-N-oxide, sulfoxide, and demethylated metabo-
lites can be separated from a mixture of all 8 reference compounds. 
This technique can be utilized for determination of sulfoxic;lation, N-
oxic;lation and demethylation of chlorpromazine by enzyme preparations. 
After spraying the paper chromatogram, Posner et al, (5) scanned 
the strips with the Spinco model. RB Analytrol whereas Kurland et al. 
(1~9) determined the metabolite by extracting into 50% H2so4 and reading 
the.acid extract at 525 mµ. in a Bauech and l,omb "Spectronic 20". Com-. 
plete extraction of the color was obtalned for CPNO with sulfuric acid 
from the thin layer separation whereas with paper this was not the case, 
Table II shows absorptiori. maximum for certain chlorpromazine metabolites 
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in the ultraviolet region. Chlorpromazine and chlorpromazine-N-oxide 
have )Jnaxat 256 mµ and almost similar spectra (Figure.4), For this 
reason.chlorpromazine-N-oxide cannot.be determined by a spectrophotome-
tric method·unless separated from chlqrpromazine. The sulfuric acid 
extracts of CP and CP-N-oxide show two peaks in.the ultraviolet region 
at 267 and 277 mµ,. Thus, the acid ~xtract of chlorpromazine-N-oxide 
can be determined at 269 mµ, 277 mµ, or.its pink color .at 525 mµ.. In 
this work, CP-N-oxide was determined at 525 mµ. 
Jollow et al, (61) determined N-oxidation of chlorpromazinebased on 
"the s NADPH oxidation by 1000 fold purified microsoinal. mixed function 
oxidase from pork. li•1er. The preparation was founc4 to be free. from de~ 
methylase, monoamine oxidase; NAPFH--cytochrome C.reductase and NADH-cy-
tochrome.C reductase, However, CP-N-oxygenase purified about 900·fold 
from pork liver in.this laboratory, catalyzes conversion of.chlorproma-
zine to Cl?NO, a small amount of N,S-dioxide and a major unidentified 
metabolite (orange when sprayed with sulfuric acid reagent, max 273.5 
mµ) in the presence of NADPH. Besides, there is the possibi:J.ity of sul-
foxi4ation .of chlorproni.azine which was.shown to require NADPH (7). In 
liver homogenate.and mictosomes, NADPH 0:11:idase·and demethylase are pre-
sent, which will also utilize NADPH, Thus, oxidation of NADPH is not 
only due to N-oxidation alone. Therefore; ei:izyme activity was based on 
the determination of CP-N-oxide by thin layer chromatography. Although 
the determination of CPNO, as an.assay technique for CP-N-oxygenase, 
requires more. time, it was · the method of choice as the .. product of the , 
reaction was determined, 
Fishman~ al. (6) reported that man excretes more mono-and dide-
methyJ,ated sulfoxide metabolites than N-oxide whereas dog excretes more 
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sulfo:dde and monodemethylated sulfoxide than N-oxide in urine. Further, 
they reported that·pharmacological and behavioral tests·on nor1 CP and 
CPNO in animal$ indicate that these compounds approach CP in activity, 
whereas CPSO is markedly less active. In the light of above·facts, it 
is of interE:)st to find that liver microsomes .. of mammalian species shown 
in Table V, produce more N-oxidation than demethylation, Beckett and 
Hewick (10) also showed occurance of N-oxidatiQn (24%), demethylation 
(12%), hydroxylation (2%) and sulfoxidation (10%), when 2. 5 µ, m of 35s 
chlorpromaz:Lne hydrochloride were incubated with male rat liver.micro-
somes (equivalent to 5.8 mg of protein) in the.presence of NADPH. 
!n 1956 Mason (150) proposed.the terms oxygen transferase and mixed 
function oxidase to denote enzymes catalyzing the over-all reactions 





At the same time, Hayaishi (150) p;roposed the term oxygenase in view of 
the·fact that the reactions catalyzed by this new group of enzymes are 
very similar to oxygenation reactions known to occur by ordinary chemi-
cal.or photochemical processes. The second type of enzyme was; there~ 
fore, referred to as a mixed function oxygenase or mixed function oxi-
dase because these enzymes are bifunctional, carrying out oxidase activ-
ity on one·s;lte and oxygenase activity on.the other. Recently the.term 
hydroxylase has been preferrec;l to mixed function oxidase or mixed func-
tion oxygenase; presumably because the former b more concise and con-
venient; Thus, the term oxygenase, i:p. a broad sense, may be 
assigned to a group of enzymes catalyzing the activation of o.xygen and 
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the subsequent incorporation of either one or two atoms of oxygen per 
mole of various substrates, The terms hydroxylase, mixed function oxy-
genase or mixed function oxidase reaction is characterized by a pair of 
requirement$: (i) oxygen is necessary, a$ a.specific·oxidizing agent, 
and (ii) an electron donor is needed as a reductant •. One of the .oxygen. 
atoms is incorporated into the substrate molecule, while the other atom 
is presumed to be simultaneou&1ly rec;luced to water (150). 
Chlorpromazi,ne-N-oxygenase requires reduced NADP, which is oxidized 
by o2 in the process. Accc;,rding to .. nomenclature. of International Union 
of '.Biochemistry, this enzyme belongs to hydroxy lase· group (l • 99 • 1); As the · 
reaction is not yet fully understood, no systematic names were recommend-
, 
), 
ed for this ty:pe·of reaction (lSl), However, namint this enzyme as 
chlorpromazine hydroxylase will be misleading because .. this enzyme does 
not catalyze hydroxylation of.chlorpromazine. Further·en.zymes were ob-
served catalyzing hydroxylation of chlorpromazine in rabbit liver micro-
somes (138). Thus, it is more appropriate to name this enzyme as chlor-
promazine-N"".oxygenase. Chlorpormazine sulfoxidation is.another process 
similar to N"".oxidation, involving reduced NADP and oxygen. (7), In the 
opinion .of the author the name "Mixed Function O;,cygenases 11 will be more 
appropriate than the name "Hydroxylases'' for this group of enzymes. 
This group may be further divided as hydroxyla~es, N-oxygenases and S-
oxygenases. Oxidation of N-atom of tertiary amine group in compounds 
such as promazine, chlorpromazine, N,N-dimethylaniline, trimethylamine 
and erythromycins, and oxidation of heterocyclic N-atom in compounds 
such.as nicotinamide and chlorcyclizine by liver microsomes.have been. 
observed. In the light of this wod;., naI!l.ing of .drug metabolizing 
enzymes is worthy of reconsideration. 
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18 Hayaishi et al. (152) showed with experiments using O, that one 
atom of molecular oxygen was incorporate<;]. into catechol by the action of 
salicylate hydroxylase, Kata,geri .!l.!1.• (153) postulated the following 
scheme for the overall reaction of salicylate hydroxylase:. 
E-FAD + · salicylate ~ E-FAD-salicylate -
E-FAD-salicylate + NAPH2 ~ E .. FADH~ - salicylate + NAD 
Here, E denotes the.protein moiety of the enzyme, Imai and Sato 
(154) reported that the interaction of P-450 with drug sul:n;trates is an .. 
obligatory step in. the mechanism of · drug hydroxy lat ions. They proposed. 
the following mechanism for aniline hydroxylation:_ 
(P-450"']+ aniline~ [ P-450"'1 - aniline· 
[ P-450' ' '] - aniline ~ [ P-450'1 - aniline 
t 
A specific microsomal electron trans-
fer pathway. 
[ l'-450''J - aniline + o2~ [ P-450". 02J - aniline 
[P-450''.02] - aniline--!)[ P-450"'] + p-aminophenol. 
where [ P-450" '] - aniline and [ P-450". o2J indicate that aniline and 
oxygen are bound to a nonheme site and the heme iron, respectively, of 
P-450. 
Guroff and Daly (155) prepared labelled 4-deuterophenylalanine and 
showed that hydroxylati,on, catalyzed by phenylalanine hydroxylase from 
liver or bacteria, yielded 3-deuterotyrosine. The hydroxylating species 
+ is not ~nown and.is referred to as HO . Mechanism for hydroxylation 
was proposed thus: 
~.COOH 




D~. o. COOH ~--...-.-,...,...,.-
0~ .JH2 . 
H~+··~.· .• ... COOR 
D~ ~ NH 
o~ . ·2 
~H 
H 
Dm·· ~ ..... · COOR 
~ .. 
~ . H2 
+H+ 
The.requirement of the oxidative microsomal enzyme systems·for 
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NA.DPli and oxygen ::t.s not completely understood. Brodie!!.&· (11) have 
postulated that a hydroxyl donor is formed during the oxidation of.NADPH 
by a microsomal NADPH oxidase·and transferred to the dri,ig substrates by 
nonspecific enzymes. Gillette and Kamm (7) proposed the following me-:-
chanism for sulfoxidat;ion of 4,4'-diaminodiphenylsulfide: 
NADPH + 02 microsomal ) (HO+J + TPN NADPH oxidase 
The mechanism of .. oxidative dealkylation has been the subject of. a 
number of studies. Horning and his associates (156,157) postulate (that 
N-oxides may be intermediate products. They have shown that liver homo-. 
genate supplemented with DPN, AMP, and ni.cotinamide catalyze the 
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rearrangement of N,N-dimethyltyrosine oxide and N,N~dimethyl tryptophan 
oxide to yield formaldehyde and.the s~condary amines. This system also 
catalyzes·the oxidation of N,N-dimethyltryptamine.to the corresponding 
N-oxide. From these observations the .. authors have proposed that the 










In support of the above pathway.Pettit and Ziegler (146,158) demonstra-
ted that rat and pig l:f,ver.microsomes catalyze.the rapid demethylation 
of N,N-dim.ethylaniline-N-oxide to methylaniline and formaldehyde in the; 
1i1,bsence of both NADPH an:d oxygen. The rate of N,N.,;dimethylanil.ine-N-
oxide demethylation by liver microsomes was sufficiently high for the. 
N-ox;Lq.e to be considered as an intermediate~ They als.o demonstrated, 
· formation of N ,N-dime.thylaniline-:-N-oxide at a st.1fficiently rapid. rate 
for it to .. be· an intermediate: in the oxidative demethylation of N,N-di-
methylaniline catalyzed by.rat or pig liver microsomes. From Table VII, 
chlorpromazine was not converted to the . N-oxide and was not .. demethylated 
to an.appreciable extent in the absence of NADPH, Thus, NADPH seems to 
be,essential for N-:-oxide fo,;mation from chlorpromazine and for oxidative 
demethylation of chlorpromazine or chlorpromazine-N-oxide by mouse liver 
I11icrosomes. It was also observed that the demethylation of.CP was 
greater·. than that , of CPNO in. tl;l.e presence of NADPH. Th:f,.s would. indicate .. 
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that CPNO is not intermediate in oxidative demethylation of chlorproma-
zine. In support of this observation, Maoand.Tardrew (159) reported. 
that.N-oxide can not be intermediate in oxidative demethylation of ery-
thromycins by rabbit tissues in vitro. This is further confirmed by the 
observation of Kuntzman ~!1· (160) that chlorcyclizine-N-oxide does 
not appear to be intermediate in the.formation of norchlorcyclizine. To 
clarify the status of the mechanism o;f demethylation, Ziegler .and co-
workers (161) reported tha.t pig liver microsomes. could catalyze the, 
dealkylation of·only those N-oxides in which the nitrogen atom was di-
rectly a.ttached to an aromatic ring. It is of. interest to note the ob-
servation of Coccia and Westerfeld (;1.37) that the ferrous ion catalyzes 
the.rearrangement of the chlorpromazine-N-oxide to nor1 CP and to CPSO 
as well as the reduction of the N-oxide to CP, However, this was not 
observed.in the presence of the ferric ion, 
Microsomal preparations isolated by the usual techniques contain a 
host of enzymes that hinder the.interpretation of·studies on the mechan-
ism of .. the oxidat.ive systems. The solubilization and purification of 
the microsomal enzyme system shoul.d proveinvaluable·in studying their 
mechanism of.action. Various drug metabolizing enzymes have been solu-
bili:zed using heated snake venom, pancreatic lipase, deoxycholate, 
freeze-thaw ultrasonication, freeze-thaw glycerol extraction and sonica-
tion fo.llowed by cholate (13). Ziegler et al. (60) solubilized alkyl-
arylamine oxygenase using sonication and addition of Triton X-100 deter-
gent. With slight modification of Ziegler's procedure and with an addi- · 
tion of protamine sulfate step, chlorpromazine-N-oxygenase has been solu~ 
bilized and purified about 900 fold from pig liver homogenate (Table 
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VIII). This purified preparation was used for studying the properties 
of the enzyme, The requirement for flavin adenine di,nucleotide by a. 
liver microsomal oxygenase catalyzing the oxidation of N,N-dimethylani-
li:p.e was observed by Ziegler!!., al. (162). From Table· IX, reduced NADP 
appears to be essential for maximumenzyme activity. 
From Figure 11, optimum pH appears to be at 8.5. In this connec-
tion it is of interest to note the observation of Hochstein and Dalton 
(163). In the.range of pH 8.2-9, nicotine oxidase activity decreased, 
when pyrophosphate or gycine buffers were employed.instead of Tris buf ... 
fer. They observed an increase in activity reaching maximum at pH 8.6 
and then the rate.remained essentia;l.ly constant up to pH 9.0, the.last. 
pH at which Tris buffers were.assayed. 
-5 Jollow !t al. (61) reported a Km value of 2, 6 x 10 M for chlor-
promazine, on the basis.of oxidat;i.on of reduced NADP by a purified mi-
crosomal mixed function oxidase from pork liver. A$ discussed earlier, 
the amount of NADPH oxidation can not yield the exact quantity of CPNO 
-3 formed. From Figure 13, we obtained a Km value of 3.57 x 10 Mon the 
basis of CPNO formed. This is comparable with Km value of 1.42 x 10-3 M 
for N,N-dimethylaniline, which is also a lipid.soluble N-methyl compound 
oxidized by pork liver microsomes (158). However, at pH 8.5, apparently 
3.5% of the substrate is soluble and the remaining chlorpromazine was 
precipitated or separates into a two phase.system. When the supernatant 
after precipitation of CP at pH 8.5, was used, the N-oxide formed was· 
only 1/36th of the amount, which formed with the same volume of 1.mpreci-
pitated CP solution. 
Chlorpromazine at the concentration of 2 x 10-3 M shows competitive 
inhibition on J::he,N-oxidation of N,N-dimethylaniline by the protamine 
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sulfate supernatant (Figure, 14). Ziegler ,!! aL (61) reported that the 
purified oxidase.from pork liver can.also catalyze the oxidation of 
other tranquilizers, antihistamines, hallucinogens, narcotics, alkaloids 
containing atropine base, ephedrine and derivatives of ephedrine. Al-
though it shows broad specificity, it will not catalyze the oxidation 
of.N-alkyl .derivatives of purines or barbiturates. In recent years, 
evidence has accumulated for the view that the.microsomes contain a num-
ber of enzyme systems which catalyze the same reaction. For example, 
\ 
there seems to be more than one N-dealkylase. This is deduced from the 
following facts: $-diethylaminoethyld:f,.phenylpropyl acetate (SKF 525A) 
(164) and iproniazid (165) inhibit the metabolism of monomethyl-4-amino-
antipyri.ne (MMAP) but do not block the dealkylation o:f; N-methyl,aniline. 
3,4-benzpyrene (53) administered to rats stimulate the dealkylation of 3-
methyl""'.MAB about five fold, but does nqt alter the rate of dealkylation 
of MMAP by liver microsomes. Results from similar experiments have 
suggested that the.liver microsomes also contain at least two.0-dealky-
lases (24) and a number of aromatic hydroxylases (166,167). A fifty to. 
70% inhibition of methanol oxidation and no signi:f;icant inhibition of 
chlorpromazine-N-oxidation (Table XI) indicates that methanol oxidase 
constitutes a separate· enzyme from CP-N-oxy.gena.se. 
From Table X, inhibition of chlorpromazine-N-oxidation by PCMB and 
iodoacetamide indicate the sulhydryl nature of this enzyme. No signifi-
cant inhibition of N-oxidation was observed by SFK-525A; This is in 
agreement with the findings of Cocc;ia and Westerfeld (137). SKF-525A, a 
potent inhibitor of microsomal drug metabolism, in concentrations as 
-4 ' low as 10 M blocks the in vitro oxidation of many drugs.including bar-
biturates, codeine and aminopyrine. In.addition, SFK-54SA inhibits the. 
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formation of morphine glucuronide and the hydrolysis of procaine. The 
microsomal enzyme, (13) that hydrolyzes the amide-linkage of monoethyl-
glycinexylidide, a metabolite of lidocaine, has been solubilized. The 
soluble enzyme,is even more strongly inhibited by SFK-525A than is the 
microsomal. preparation. Although. SKF-525A inhibits the dealkylation of 
N,N-dimethylaniline-N-oxide, it does not inhibit the N-oxidation of N, 
N-dimethylaniline (168). Coccia.and Westerfeld (137) reported that SKF-
525A does .not inhibit CP-N-oxidation and N-oxide reduction but inhibits 
demethylation, sulfoxidation and hydroxylation of chlorpromazine by rat 
and human liver microsomal enzyme systems. Gillette and Kamm (7) repor-
ted that SKF-525A does not inhibit sulfoxidation of chlorpromazine by 
guinea pig liver microsomes. 
Little or no inhibition by cyanide and azide (Table X) indicates 
that hemoprotein is not involved in the CP-N-oxidation reaction mechan-
ism but a slight inhibition by EDTA suggests a metal involvement. The 
presence in mammalian liver microsomes of a carbon monoxide-binding pig-
ment has been reported by Klingenberg and Garfinkel '(147). The CO com-
pound of the reduced pigment has an intense absorption band at 450 mµ 
and thus can be readily detected in dithionite-treated microsomes by 
difference spectrophotometry. Omura and Sato (169) reported evidence 
for the hemoprotein nature of the microsomal CO-binding pigment, pro-
visionally called "P-450" and have shown that it can be.converted into a 
solubilized form, which was called "P-42011 , by treatment of microsomes 
anaerobically with snake venom or.deoxycholate. Recent studies have 
established that P-450 is involved as the oxygen activating enzyme in a 
number of NADPH-requiring monooxygenase reactions such as drug hydroxy-
lations by liver mictosomes and steroid hydroxylations by adrenal cortex 
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microsomes and mitochondria (170). Imai and Sato (154) collected evi-
dence indicating that the drug-induced spectral changes are closely re-
lated to the mechanism of drug hydroxylation by liver microsomes and 
that P-450 is actually involved in these changes and functions in the. 
substrate activation. Participation of cytochrome P-450 was also repor-
ted in.omega oxidation of fatty acids (171). As the CP-N-oxygenase is 
purified, instead of an increase in the ratio of cytochrome to protein, 
P-450 is decreased followed by an increase in p:..420 (Table XII). This 
indicates that during purification procedure P-450 is partly solubilized 
and further supports the suggestion that P-450 is not involved in N-oxi-
dation reaction. In confirmation of the,above, after the 10th day the 
preparation did not show the presence of P-450, though it possessed 
about 70% of the N-oxygenase activity. Ziegler and Pettit (168) repor-
ted that carbon monoxide does. not inhibit N-oxidation of N,N-dimethylani-
line but inhibits the subsequent dealkylation of the N-oxide to the 
secondary amine and aldehyde. Ziegler !l al. (172) further reported 
that P-450 is an.essential pigment in the dealkylation reaction but is 
not involved in the initial N-oxidation of N,N-dimethylaniline. Esta-
brook et al. (173) reported the absorption spectral properties of two --
forms of cytochrome P-450 in rabbit liver microsomes inducible preferen-
tially either by phenobarbital or 3-methylcholanthrene. 
In conclusion, cytochrome P-450 does not appear to be.involved in 
the N-oxidation reaction mechanism, whereas involvement of P-450 has 
been established in hydroxylation reactions by other workers. Further 
purification by gel filtration and development.of more sensitive methods 
using radioactive chlorpromazine for determination of CPNO will be more. 
useful in elucidation of mechanism of.N-oxidaticn reactions. 
SlJMMARY 
Chlorpromazine (CP) was '"Converted. to chlorprom.azine-N-oxide by 
mammalian liver microsomal preparations. The assay·system developed 
for.chlorpro1'1azine-N-oxygenase was based on.a thin-layer chromatographic 
separation of CP metabolites •. The enzyme system catalyzing the,NADPH-
dependent oxtdation of the side chain N-atom of.CP was found to be main"':' 
ly in the microsomes. CP-N-oxidation and demethylation by liver.micro-
somes of mouse; rat; dog, pig and bovine were measured. Production of. 
N-oxide by different species was. in the following order: . dog =. mouse > 
pig > rat >bovine. CP-N-oxyget1.ase was solubilizeci using sonication 
follow1;ad. by addition of Triton X-100. This enzy1').e.was f~rther purified 
by ammonium sulfate fractionation.and protamine sulfate, The purified 
enzyme showed about .900 fold purification from the liver. homogenate or 
18 fold from liver microsomes. The·enzyme has a Kin value of 3.57 x 10-3 
' • t •• 
M for chlorpromazine and showed .. a pH optimum at 8.5. The temperature 
was optimum.between 30-37°c and loses about 70% activity at 45°c. 
SKF-525A does not· show any significant .. inhibition of. N-oxidation. Inhi-
bition by PCMB and.iodoacetamide indicates the sulfhydrayl·natute of the 
enzyme •. A comparison of the effects of cyanide and azide on inhibition 
of methanol oxidation and.CP..-N-oxidation, indicates that.CP-N-oxygenase · 
constitutes a separate enzyme .. system from methanol oxidase. Chlorpro-
-3 mazine at a.concentration of 2 x 10 M show1:1 compet!tive inhibition on 
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the N-oxidation of N,N-dimethylaniline by protamine sulfate.supernatant. 
Little or.no inhibition on CP-N-oxidation by cyanide and azide indicate 
that hemoprotein is not involved in this N-oxidation reaction mechanism 
but a slight inhibition by EDTA suggests a metal involvement, It is 
fur~her confirmed by CO difference spectra that P-450 is not involved 
in CP-N-oxidation reaction mechanism. 
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